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Antioxidant enzymes play important roles in maintaining the cellular redox 
homeostasis and protecting cell from damage caused by reactive oxygen species 
(ROS). Copper,zinc superoxide dismutase (SOD1) is an important antioxidant enzyme 
responsible for the clearance of superoxide anion. It has been suggested that the 
deficiencies of superoxide dismutases lead to abnormal lipid deposition in different 
organs. However, the regulatory role of SOD1 in lipid metabolism is largely unknown. 
The objective of this study was to determine the role of SOD1 in lipid metabolism. 
The experiments were conducted on the young and adult SOD1 knockout (SOD1-/-) 
and WT mice fed high fat, copper deficient, copper excess, or normal diets. Under the 
normal conditions, the SOD1 knockout causes hypercholesterolemia and 
hypotriglyceridemia with irregular lipids accumulation in liver, heart, kidney, muscle 
and testis. In contrast to the suppressed accumulation of fatty acids/triglyceride, the 
cholesterol synthetic pathway was consistently activated in SOD1-/- mice as indicated 
by increased mRNA and protein levels of related genes. The significant increase of 
sterol regulatory element binding proteins (SREBP) 2 and decrease of SREBP1 in 
SOD1-/- mice were observed. SOD1-/- mice fed high fat diet had reduced body weight 
and very low density lipoproteins (V)LDL triglyceride, although the total plasma 
cholesterol, total triglyceride and fecal cholesterol was not significantly affected. 
Copper deficiency did not affect the concentrations of blood lipids in SOD1-/- mice 
   
 
while high copper was found only to reduce hepatic triglyceride level without effect 
on plasma cholesterol and triglyceride levels as well as hepatic cholesterol. 
Surprisingly, significant increase of total plasma cholesterol was observed in mice 
injected with herbicide diquat (DQ) in addition to the increased mRNA levels of 3 
–hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) and squalene epoxidase. 
HepG2 cells showed similar responses to diquat treatment with increased HMGCR 
mRNA level. In conclusion, knockout of SOD1 caused disorder in lipid metabolism 
associated with the increased transcription of genes involved in cholesterol synthesis. 
These changes were not reversed by the high fat diet or dietary copper 
supplementation and might be dependent on increased ROS level following loss of 
SOD1 function. 
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CHAPTER ONE 
INTRODUCTION 
Oxygen, a final acceptor of electrons in the reactions of respiration coupled with 
oxidative phosphorylation, is indispensible to aerobic organisms because of energy 
production. However, it is also a potentially toxic molecule because of the formation 
of reactive oxygen species (ROS). The survival of all metazoan organisms depends on 
the balance between the generation of energy and production of potentially toxic 
oxidants (1). An antioxidant system, including copper (Cu), zinc (Zn) superoxide 
dismutase (SOD1), makes cells capable of coping with these potentially toxic 
molecules, and simultaneously maintains the cellular redox homeostasis which affects 
the cellular signal transduction. The importance of SOD1 has been recognized because 
it catalyzes the first step of clearance of superoxide. A number of studies have been 
conducted to investigate the protective roles of SOD1 in different tissues and organs, 
such as brain, eyes, muscle, and liver (2-9). Linked to the energy metabolism by 
oxygen, the precursor of superoxide, SOD1 possibly plays an important role in 
regulation of energy homeostasis and lipid metabolism in cells.  
 
1.1 Reactive Oxygen Species (ROS) 
Reactive oxygen species  are derived from the metabolism of molecular oxygen, 
including superoxide anion radical (O2-.), singlet oxygen (1O2), hydrogen peroxide 
(H2O2), and hydroxyl radical (.OH) (10). A one-electron reduction of O2 results in the 
formation of superoxide either by enzymatic catalysis or by “electron leaks” from 
various electron transfer reactions. In contrast to its remarkable stability in many 
organic solvents, superoxide in aqueous solution is short-lived (11). Unlike superoxide, 
H2O2 is not a free radical and is a much more stable molecule. H2O2 is able to diffuse 
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across biological membranes, whereas superoxide does not (12). H2O2 is a weaker 
oxidizing agent than superoxide. However, in the presence of transition metals such as 
iron or Cu, H2O2 gives rise to the indiscriminately reactive and toxic hydroxyl radical 
by Fenton chemistry (13).  
Due to their higher reactivities relative to molecular O2, ROS are potentially toxic to 
cells, and have wide effects on biological molecules, including proteins, nucleotides, 
carbohydrates and lipids (14). The term oxidative stress refers to damage to these 
molecules that occurs when ROS generation is higher than the clearance ability of the 
antioxidant system (15). Several markers which may indicate the oxidative stress level 
induced by ROS have been identified：1) protein carbonyls are chemically stable 
biomarkers of oxidative stress. Carbonyl groups are generated by direct oxidation of 
amino acid residues, particularly lysine, arginine, threonine, and proline, or by 
secondary reaction with the primary oxidation products of sugars and lipids; 2) the 
most representative product that may reflect oxidative damage to DNA in the cells is 
8-hydroxy-2-deoxyguanosine (8-OHdG), a product of oxidatively modified DNA base 
guanine; 3) malonaldehyde (MDA) is one of the end products of lipid peroxidation in 
the cell membranes or in low-density lipoproteins, and F2-Isoprostanes, especially 
8-iso-PGF2, also have been proposed as specific, reliable, and non-invasive markers 
of lipid peroxidation in vivo (16-18). These molecules could be used as clinical 
markers to evaluate the damage caused by ROS because their levels are very low in 
normal animal biological fluids and tissues (18).  
In addition to their deleterious effects on cells, ROS have been proven to act as 
important signaling molecules in the cell. Early studies have shown that H2O2 has an 
insulin-like effect on glucose transport and oxidation, and enhances lipid synthesis 
from glucose in adipocytes (19, 20). Mitogen-activated protein (MAP) kinase 
signaling pathways are well known to be activated by ROS which induce the 
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phosphorylation of downstream proteins, extracellular signal-regulated kinase (ERK), 
c-Jun N-terminal kinase (JNK) and p38 MAP kinase, as widely observed earlier (21). 
It has been suggested that mitochondrial ROS are involved in the process of apoptosis 
induced by TNF- α and IL-1 β , while mediating the hypoxia-induced gene 
transcription (22, 23). ROS derived from NADPH oxidase in vascular smooth muscle 
cells regulate the vascular remodeling (24). Recently, protein tyrosine phosphatase-1B 
(PTP1B) has been identified as a ROS-responsive protein, which could be directly 
oxidized and inactivated by superoxide and hydrogen peroxide (25, 26). As PTP1B is 
a key regulator of multiple signaling pathways downstream of receptor tyrosine 
kinases, it provides a possible target for manipulating cellular responses through ROS. 
Another example is NF-E2-related factor-2(Nrf2)-Keap1 complex, which functions as 
a ROS sensor and regulates the expression of antioxidant enzymes, such as catalase 
(CAT) and glutathione peroxidase 1 (GPX1), through the binding of antioxidant 
response elements (AREs) in their 5’-flanking promoter regions (27, 28). Other factors 
including NF- B, SP1, and YY1 are also involved in the regulation of redox-induced 
changes (29-31). Therefore, in addition to oxidative damage, ROS are critical to 
maintain normal physiological reactions. 
As potentially toxic molecules, ROS are strictly regulated by the antioxidant system 
which is made up of antioxidant enzymes and small antioxidant agents. Superoxide 
generated by the mitochondria and other sources is converted to H2O2 and O2 by 
superoxide dismutases (SODs), and H2O2 is then catalyzed to water by GPX1 and 
CAT (32, 33). Therefore, SODs provide an important defense against superoxide 
toxicity. Depending on the species, there are up to three different metal-containing 
SOD enzymes which, taken together, make up the major superoxide scavenging 
system in the mitochondrion, nucleus, cytoplasm and extracellular spaces. These 
SODs are the products of different genes and are historically designated, in higher 
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eukaryotes, by their primary location as follows: SOD1 (cytoplasmic Cu, Zn SOD), 
SOD2 (mitochondrial manganese SOD) and SOD3 (extracellular Cu, Zn SOD). The 
majority of superoxide in mammalian cells is generated by chemiosmotic proton 
transfer by Complex I and III during mitochondrial ATP production. Superoxide 
produced by Complex I is exclusively released into the mitochondrial matrix and 
dismutated by SOD2, whereas Complex III can release superoxide to both 
extra-mitochondrial and intra-mitochondrial matrix locations, where the superoxide is 
dismutated by SOD1 and SOD2, respectively (34). The different types of SODs have 
different roles in maintaining the entire cellular redox environment. 
Superoxide is subjected to rapid spontaneous dismutation in aqueous solutions, 
especially when its concentration reaches a high level in acidic pH conditions. SOD 
speeds up this reaction almost 104-fold and the rate constant reaches 1.6×109 M-1 s-1 
(35). Nitric oxide is another biomolecule, which is able to outcompete SOD,  and 
reacts with superoxide at near diffusion-limited rates to form peroxynitrite (36). This 
reaction provides another significant biological outlet of superoxide because 
peroxynitrite is a much more active molecule that could nitrate the residues of protein 
(37). Nitrotryrosine is one of its end products and it may induce alteration of protein 
conformation leading to changes in enzyme catalytic activity, signal transduction, 
cytoskeletal organization and inhibition of tyrosine phosphorylation by protein kinase 
(38). The significance of protein nitration has also been shown in aging, 
neurodegeneration and cancer (39, 40).   
 
1.2 Superoxide Dismutase (SOD) 
Cu, Zn superoxide dismutase is the major cellular isoform of superoxide dismutase, 
and it is encoded by the SOD1 gene. It is a homodimer of molecular weight 32,500 
Daltons and the two subunits that joined primarily by hydrophobic and electrostatic 
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interactions (41). It is mainly located in cytosol, but also found in the intermembrane 
space of the mitochondria in which SOD1 might be involved in the protection of 
mitochondrial proteins from the superoxide-induced damage (42). In addition to its 
superoxide dismutase activity, SOD1 can function as a superoxide reductase (SOR), 
and as a superoxide oxidase (SOO) while Mn SOD does not have SOR or SOO 
activities (43). These differences, in addition to the cellular localization, may be 
related to their biological functions. 
Studies have shown that SOD1 is an indispensible antioxidant enzyme to maintain the 
normal redox environment and physiological reactions in cells. Mutant SOD1 has 
been widely linked to neurodegenerative diseases. Up to 25% of familial amyotrophic 
lateral sclerosis (FALS) are associated with mutations in SOD1 (44). However, the 
proposed pathogenesis of mutant SOD1 is not because of the loss of functional activity, 
but of the gain of toxic properties of mutant SOD1 (45, 46). Due to the additional 
deleterious property of mutant SOD1, knock out or over expression of SOD1 gene 
provides more specific tools for functional studies. Knockout studies indicate that 
deficiency of SOD1 results in the widespread oxidative damage and induces various 
symptoms/phenotypes, related to liver (2-4), eyes (5, 6), infertility (7), neuron (8), 
muscle (9), kidney (47) and erythrocyte (48) in rodent models. For example, SOD1 
deficient mice display a decreased life span and an elevated incidence of liver cancer 
with an increased frequency of DNA mutation and apoptotic cells (2, 4). Without the 
protection of SOD1, ethanol accelerates the functional loss of mitochondria by 
inducing uncoupling, swelling, changing the permeability transition and decreasing 
adenine nucleotide translocator activity, which leads to the development of necrosis in 
the alcohol-induced liver injury (3). The deletion of SOD1 also increases the 
ischemia/reperfusion-induced acute renal failure in mice (47). By contrast, over 
expression of SOD1 is proved to reduce the superoxide radical level and oxidative 
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stress. Over expression of SOD1 causes a significant decrease of superoxide 
production, which affects redox-sensitive inflammatory signaling and neurotoxic 
inflammation process in microglia (49). The activation of NF-kappa, regulated by 
ROS, is attenuated by the over expression of SOD1 after transient focal cerebral 
ischemia, and it blocks the expression of downstream deleterious genes like c-myc, 
thereby reducing ischemic damage in mice (50). So, the deficiency of SOD1 exposes 
cells to the deleterious superoxide while over expression of SOD1 blocks the signal 
transduction of superoxide.  
Besides the antioxidant activity, SOD1 itself has been found to function as a signal 
molecule interacting with other proteins. SOD1 can interact with ERα and enhance 
binding of ERα  to estrogen response element-containing DNA (51). SOD1 is required 
for the effective estrogen responsiveness of the endogenous pS2, progesterone receptor, 
cyclin D1, and cathepsin D genes in MCF-7 breast cancer cells (51). This suggests the 
additional function of SOD1, which is different from enzymatic activity. Another 
possible role of SOD1 is metal chelator for Cu and Zn in cells to maintain the metal 
homeostasis. Knock out of SOD1 results in a 50% decrease of Cu in the liver of 
3-month-old mice while it causes a 50% increase of hepatic iron as well (52).  
 
1.3 Cholesterol and Hypercholesterolemia 
Cholesterol, an amphipathic lipid, is an essential structural component of the cell 
membrane and outer layer of blood plasma lipoproteins. Moreover, cholesterol is a 
precursor of several other steroids, namely corticosteroids, sex hormones, bile acids, 
and vitamin D in animals. Cholesterol in animal body originates from two major 
sources, dietary intake and de novo synthesis. Dietary cholesterol comes mainly from 
animal products, while food of plant origin contains no cholesterol. In animals, 
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cholesterol can be synthesized in most tissues from acetyl-CoA, and liver is a primary 
organ for cholesterol synthesis (~40%) in mice (53). 
The process of cholesterol synthesis occurs in the endoplasmic reticulum (ER), 
microsomes and cytosol from the two-carbon acetate group of acetyl-CoA, which is 
generated in the mitochondria primarily from two sources, the pyruvate 
dehydrogenase (PDH) reaction, and fatty acid oxidation and is delivered to the 
cytoplasm. It is noted that acetyl-CoA is the same substrate for both cholesterol and 
fatty acid synthesis in the cytosol, and it represents different directions of energy flux 
in cells. For cholesterol synthesis, two molecules of acetyl-CoA are condensed in a 
reversal of the thiolase reaction, forming acetoacetyl-CoA. Acetoacetyl-CoA and a 
third molecule of acetyl-CoA are converted to HMG-CoA by the action of HMG-CoA 
synthase. Unlike the HMG-CoA produced during the synthesis of ketones in the 
mitochondria, this form is synthesized in the cytoplasm. However, both pathways 
share the necessary enzymes. Then HMG-CoA is converted to mevalonate by 
HMG-CoA reductase (HMGR) which is bound in the ER membrane. The reaction is 
the rate-limiting step of cholesterol biosynthesis, and HMGR is a target for clinical 
cholesterol-lowering drugs such as statins. 
As a precursor for biologically important nonsteroidal isoprenoids, mevalonate is then 
converted to 3-isopentenyl pyrophosphate in three reactions which require ATP. This 
molecule is decarboxylated to isopentenyl pyrophosphate, which is a key metabolite 
for various biological reactions. Three molecules of isopentenyl pyrophosphate 
condense to form farnesyl pyrophosphate through the action of geranyl transferase. 
Two molecules of farnesyl pyrophosphate then condense to form squalene by the 
action of squalene synthase, which is the first enzyme in the committed cholesterol 
pathway. Squalene is converted to 2, 3- oxidosqualene by squalene epoxidase, which 
requires NADPH as a reductant and O2 as an oxidant. This is the first oxidation step in 
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cholesterol synthesis. Oxidosqualene cyclase then cyclizes 2,3- oxidosqualene to form 
lanosterol. Finally, lanosterol is then converted to cholesterol involving 19 reactions, 
catalyzed by enzymes associated with ER membranes. De novo synthesized 
cholesterol as well as dietary source cholesterol is utilized in the formation of 
membranes and the synthesis of the steroid hormones, bile acids and others, and the 
greatest proportion of cholesterol is used for bile acid synthesis in hepatocytes. 
Although the ER is the primary site of cholesterol synthesis, the concentration of 
cholesterol in the ER is very low, comprising only about 0.5–1% of cellular 
cholesterol (54). De novo synthesized cholesterol is mostly transported from the ER 
directly to the plasma membrane, bypassing the Golgi apparatus, but some follows the 
vesicle-mediated protein secretory pathway from the ER to the trans-Golgi network 
(55). Excess cholesterol in the ER becomes esterified (CE) by acyl-CoA: 
cholesterol acyltransferases, after which the cholesterol esters are stored in lipid 
droplets. Cholesterol can be removed from cells by efflux to extracellular acceptors, 
especially apoA-I and HDL, which transports cholesterol from extra hepatic tissues to 
the liver (56, 57). Alternatively, part of the liver cholesterol may be esterified, 
incorporated into the nascent VLDL particle, and secreted into the plasma to be used 
by peripheral tissues (58).  
As cholesterol is almost insoluble in water, it is stored in lipoproteins in the circulatory 
systems, which includes chylomicrons, very low density lipoprotein (VLDL), 
intermediate density lipoprotein (IDL), low density lipoprotein (LDL), and HDL. 
Many of these lipoproteins are named based on its density while they carry different 
amount of lipids inside. Chylomicrons mainly carry triacylglycerol, with certain 
amount of dietary cholesterol, from the intestines to the liver, skeletal muscle, and to 
adipose tissue. VLDL carries newly synthesized cholesterol and triglyceride from the 
liver to peripheral tissues. Once depleted of its triacylglycerol, the VLDL is 
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transformed into cholesterol-rich remnant particles LDL. LDL can be removed from 
the plasma by receptor-dependent and receptor-independent mechanisms. 
Receptor-dependent LDL uptake accounts for 60–80% of LDL clearance, most of 
which occurs in the liver (59). IDL is the intermediate between VLDL and LDL. 
HDLs are the smallest and densest class of lipoprotein and are produced in nascent 
form by the liver and the intestine. The role of HDLs are to transport of cholesterol 
from peripheral tissues, including the artery wall, either directly or via other 
lipoproteins, to the liver, which is the main reason why HDL-bound cholesterol is 
sometimes called "good cholesterol". In contrast, high levels of LDL cholesterol can 
signal medical problems like cardiovascular diseases, so it is sometimes called "bad 
cholesterol".  
Hypercholesterolemia is a condition characterized by a very high level of cholesterol 
in the blood (60). It is not a disease but a metabolic derangement that can be secondary 
to many diseases and can contribute to many forms of different diseases, most notably 
cardiovascular disease. Elevated cholesterol in the blood is due to abnormalities in the 
levels of lipoproteins, the particles that carry cholesterol in the bloodstream. Many 
factors, such as diet, receptor dysfunction and hormones, which can affect cholesterol 
metabolism and transport, may cause this abnormality. It results from a combination 
of genetic and environmental risk factors. People with hypercholesterolemia have a 
high risk of developing a form of heart disease called coronary artery disease. This 
condition occurs when excess cholesterol in the bloodstream is deposited in the walls 
of blood vessels, particularly in the arteries that supply blood to the heart. The 
abnormal buildup of cholesterol forms clumps that narrow and harden artery walls. As 
the clumps get bigger, they can clog the arteries and restrict the flow of blood to the 
heart. The buildup of plaque in coronary arteries causes a form of chest pain called 
angina and greatly increases a risk of heart attack.  
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The most common inherited hypercholesterolemia is known as familial 
hypercholesterolemia, which results from mutations in the LDLR gene (61). Less 
commonly, hypercholesterolemia can be caused by mutations in the apolipoprotein B 
(APOB), low density lipoprotein receptor adaptor protein 1 (LDLRAP1), or proprotein 
convertase subtilisin/kexin type 9 (PCSK9) genes (62-64). Mutations in the APOB 
gene result in a form of inherited hypercholesterolemia known as familial defective 
apolipoprotein B (FDB) (63). LDLRAP1 mutations are responsible for another type of 
inherited high cholesterol, autosomal recessive hypercholesterolemia (ARH) (64). 
Proteins produced from the APOB, LDLRAP1, and PCSK9 genes are essential for the 
normal function of low-density lipoprotein receptors (62). Mutations in any of these 
genes prevent the cell from making functional receptors or alter the receptors' function 
and cause severely elevated LDL cholesterol (LDL-C) levels (65). As the excess 
cholesterol circulates through the bloodstream, it is excessively deposited in tissues 
such as the skin, tendons, and arteries causing severe health consequences.  
Other factors, such as diet, smoking and a life-style, are known to cause or associate 
with hypercholesterolemia (66, 67). High fat diet can induce hypercholesterolemia in 
mice and humans with increased LDL cholesterol (66). A strong positive association 
has been observed between prevalence of hypercholesterolemia and smoking habits, 
while an inverse association between hypercholesterolemia and adherence to a 
Mediterranean diet (67). 
 
1.4 Signals Controlling Cholesterol Synthesis 
In mammals, regulation of cellular cholesterol content intertwines cellular uptake, 
biosynthesis, degradation and secretion. Multiple feedback mechanisms that control 
uptake and synthesis at the transcriptional and posttranscriptional level mainly dictate 
the cholesterol homeostasis in most cells, while degradation and secretion of 
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cholesterol also highly contribute to the cellular cholesterol level in hepatocytes. 
SREBPs, discovered in 1993, are transcription factors that regulate the expression of 
genes involved with cholesterol and fatty acid metabolism (68). They are considered 
as master regulators of cholesterogenesis and lipogenesis. There are three different 
SREBPs: SREBP-1a, -1c and -2. SREBP-1a and -1c are isoforms produced from a 
single gene by alternate splicing (69). SREBPs are basic-helix-loop-helix-leucine 
zipper transcription factors synthesized as inactive precursors bound to the ER 
membrane (70). In the ER, the C terminus of the SREBP interacts with a protein called 
Scap (SREBP-cleavage activating protein), which functions as a sterol sensor, specific 
to the cholesterol level (71-74). Another sterol sensor is Insig (an insulin induced gene) 
which is an oxysterol binding protein different from Scap (71). When cells have 
sufficient sterol, Scap and Insig bind its specific sterol, which promote the binding of 
each other and prevent ER exit of SREBP (75, 76). In sterol-depleted cells, Scap does 
not bind to Insig, allowing ER exit of SREBP-Scap via COPII vesicles (73). Scap 
escorts the SREBPs from the ER to the Golgi, where they are processed by two 
membrane-associated site 1 and site 2 proteases (S1P and S2P), which release the 
mature forms of the proteins (77, 78). These transcriptionally active fragments of the 
SREBPs translocate to the nucleus, where they bind to the promoters of SREBP target 
genes, including genes involved in the synthesis and metabolism of cholesterol, 
triglyceride, and fatty acid (79-81).  
In addition to the direct regulation of SREBPs on the biosynthetic pathway, 
peroxisome proliferator-activated receptors (PPARs) also regulate diverse aspects of 
lipid metabolism, including fat mobilization, fatty acids oxidation, and fat cell 
development (82-84). Moreover, liver X receptors play essential roles in the regulation 
of cellular cholesterol flux, whole body cholesterol absorption and excretion, and in 
the biosynthesis and oxidation of fat (85-89). However, fatty acids and cholesterol 
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metabolites in nucleus can function as natural ligands and regulate the DNA binding 
activity of PPARs and LXRs (90, 91). Different from the nuclear transcription factors, 
hormones like insulin and glucagon are also important in regulating lipid metabolism 
(92, 93). 
HMG-CoA reductase is the rate-limiting enzyme of cholesterol synthetic pathway, and 
its total activity indicates the rate of cholesterol synthesis. This is a transmembrane 
glycoprotein, located on the ER, which catalyzes the four-electron reduction reaction 
of HMG-CoA to coenzyme A and mevalonate (94, 95).  The activity of HMG-CoA 
reductase is regulated through synthesis, degradation, and modification in order to 
maintain the proper concentration of mevalonate derived products (96, 97). When cells 
are depleted of cholesterol, transcription of HMG-CoA reductase is activated through 
the binding of SREBP to promoter region of HMG-CoA reductase gene (73). 
Interestingly, transmembrane segments of HMG-CoA reductase contain a 
sterol-sensing domain, and products of both the sterol and isoprenoid pathway 
accelerate the degradation of HMGCR by an ubiquitin-proteasome dependent pathway 
(98). It is noted that the sterol intermediates lanosterol and 24,25-dihydrolanosterol, 
rather than the end product cholesterol, stimulate HMGCR degradation (99). HMGCR 
is also subject to posttranslational modification that regulates enzyme activity. 
Phosphorylation of hepatic HMGCR by calcium-activated and 
phospholipid-dependent protein kinase or AMP-activated protein kinase reduces its 
activity, and it is proposed to protect cells by limiting ATP expenditure in response to 
metabolic stress (100-102). 
 
1.5 Copper Homeostasis on Hypercholesterolemia 
Cu, an essential nutrient has to be obtained from the diet to meet the normal 
physiological needs. Otherwise Cu deficiency occurs and causes metabolic alterations, 
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including hypercholesterolemia and lipid disorders (103-106). Cu deficiency-induced 
hypercholesterolemia has been documented for decades. Cu deficiency induces 
hypercholesterolemia with 30 to 40% increases of plasma total cholesterol by most 
studies (103, 104, 107). In rats, HDL and LDL cholesterol, and triglyceride are 
consistently elevated by Cu deficiency, while VLDL cholesterol varies between 
studies (103, 108, 109); Cu deficiency also decreases hepatic total cholesterol 
concentration (108, 110). However, hepatic 3-hydroxy-3- methylglutaryl coenzymeA 
(HMG CoA) reductase activity is increased by Cu deficiency, which catalyzes the 
rate-limiting step of cholesterol biosynthesis. The increased synthesis is responsible 
for the high net efflux of cholesterol from liver to plasma in the Cu deficient rats (111). 
Hepatic fatty acid synthase (Fasn) is also induced by Cu deficiency in rats (112). The 
degradation and secretion of cholesterol could reduce cholesterol level in the body, but 
unlikely account for the Cu deficiency induced hypercholesterolemia, which could be 
inferred from the results of studies with radiolabeled cholesterol in Cu deficient rats 
(103, 113). On the other end, the excess Cu could reduce the hepatic and plasma 
cholesterol. In Wilson disease, elevated hepatic Cu results in the development of liver 
pathology (114). Most importantly, high Cu suppresses the transcription of HMG CoA 
reductase inspite of the increased SREBP2 in liver of the mouse model of Wilson 
disease (115). It shows a 3.6-fold decrease of VLDL cholesterol in serum and a 33% 
decrease of liver cholesterol (115). In conclusion, these studies suggest that Cu has a 
significant impact on lipid metabolism. 
 
1.6 Objectives 
For the first time we observed the severe lipid disorder in mice caused by the knockout 
of SOD1, although deficiencies of antioxidant enzymes, including SOD1 and SOD2, 
showed to cause certain metabolic alterations related to energy and lipids metabolism 
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as reported. However, the role of SOD1 in lipid metabolism has not been studied well 
and the mechanism behind the phenotype remained unknown. The present study was 
conducted to explore the molecular mechanism of the regulation of lipid metabolism 
in SOD1-/- mice with nutritional and molecular approaches. 
Based on the previous characterization of phenotype and molecular studies on the 
SOD1-/- mice at different developmental stages under normal conditions, we 
developed and tested a series of hypotheses: 1) the metabolic changes induced by the 
knockout of SOD1 depended on the dietary energy intake, which could be reversed by 
high fat diet (Chapter Four); 2), the dietary Cu may counteract the metabolic changes 
induced by the knockout of SOD1 (Chapter Five), and, 3) ROS are the primary factors 
in regulation of cholesterol biosynthesis which accounts for the increased plasma 
cholesterol (Chapter Six). A general conclusion and discussion was stated in Chapter 
Seven. 
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CHAPTER TWO 
GENERAL MATERIAL AND METHODS 
2.1 Animals and Diets 
All experiments are approved by the Institutional Animal Care and Use Committee at 
Cornell University and conducted in accordance with the NIH guidelines for animal 
care. The SOD1 knockout (SOD1-/-) and wild-type (WT) mice generated from 
129SVJ x C57BL/6 strain，were generously provided by Y. S. Ho of Wayne State 
University, Michigan  (116). Mice were kept on a 12-h-light/12-h-dark cycle in a 
ventilated room with controlled temperature (20–23°C) with the light phase beginning 
at 7:00 am. All mice were caged with free access to basic or experimental diet and 
distilled water. Genotypes of mice were verified by DNA analysis using a polymerase 
chain reaction method. Primers for detection of SOD1 (+) and (-) are: Forward primer: 
5’-GGACATCGTGTGATCTCACTCTCAGGAGAG-3’; WT reverse primer 
5’-CAAGCGGCTCCCAGCATTTCCAGTCTTTGT-3’; Knockout reverse primer: 
5’-AAAAGCGCCTCCCCTACCCGGTAGAATTGA-3’.  
Mice were a fed diet as shown in Table 2.1. The diet contained 30% torula yeast, 58.6% 
sucrose, and 5% tocopherol-stripped corn oil. Vitamin and mineral mix were prepared 
and added into the diet. Selenium was added into the diet by mixing a stock solution of 
0.1 mg Se/ml as Na2SeO3. Torula yeast was purchased from Rhinelander Paper 
Company, Inc., Lake States Division (Rhinelander, WI) and contained less than 0.02 
mg Se/kg by analysis. Sucrose, corn oil, DL-methionine and vitamin E 
(DL-alpha-tocopheryl acetate, 500 IU/g) were purchased from Dyets Inc. (Bethlehem, 
PA). 
 
2.2 Cell Culture 
HepG2/C3A human hepatocellular carcinoma cells (American Type  Culture 
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Table 2.1 Composition of mouse diet
1 
 
Ingredient  Amount (g/kg)  
Torula yeast  300.0  
Sucrose  585.9  
Corn oil  50.0  
DL-methionine  4.0  
Choline chlorine  1.0  
Vitamin E  0.1  
Mineral mix
2
 50.0  
Vitamin mix
3
 9.0  
1 
Diet is supplemented with Se (Na2SeO3) at 0.4 mg/kg.  
2 Mineral mix ingredients (per kg diet): CaCO3, 26.34 g; MgCO3, 1.25 g; MgSO4, 
0.79 g; NaCl, 3.45 g; KCl, 5.4 g; KH2PO4, 10.6 g; ferric ammonium citrate, 1.03 g; 
KI, 4 mg; MnSO4•H2O, 0.17 g; NaF, 50 mg; AlNH4(SO4)2•12H2O, 8 mg; 
CuSO4•5H2O, 45 mg; CrCl3•6H2O, 26 mg.  
3 Vitamin mix ingredients (per kg diet): sucrose, 8.8 g; thiamin•HCl, 4.0 mg; 
riboflavin, 2.5 mg; pyridoxine•HCl, 2.0 mg; calcium D-pantothenate, 20.0 mg; niacin, 
100.0 mg; menadione sodium bisulfide, 3.0 mg; folic acid, 2.0 mg; D-biotin, 1.0 mg; 
vitamin B12 (0.1%), 10 mg; vitamin A (650 IU/mg); 38.5 mg; vitamin D (400 IU/mg), 
5.0 mg. 
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Collection CRL-10741) were grown in a humidified incubator at 37°C and 5% CO2 in 
Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine 
serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM L-methionine, 1x MEM 
nonessential amino acid solution, 100 units/ml penicillin and 100 μg/ml streptomycin. 
Prior to subculturing, the cells were removed from 100-mm-diameter culture dish 
using 1 x trypsin solution, washed and re-suspended in fresh complete medium, and 
replated either in new culture dishes or in 6-well tissue culture plates. Treatment 
studies were performed within 24 h after reaching 60-70% confluence. 
 
2.3 Sample Collection and Processing 
Blood samples were collected from mice through heart puncture with an EDTA-coated 
syringe immediately after anesthetization with carbon dioxide. Plasma was separated 
by centrifugation at 3,000×g for 5 min at 4℃. Tissue samples were collected, rinsed 
in 0.9% saline, frozen in liquid nitrogen, and stored at -80℃ prior to use. Frozen 
livers were homogenized (Polytron PT3100; Brinkmann Instruments, Littau, 
Switzerland) in buffer I, II or III. Samples homogenized in buffer I and II were 
centrifugated at 12,500×g for 20 min at 4℃ (Labnet Spectrafuge, National Labnet 
Co., Edison, NJ). Supernatants in buffer I were used for Western blot analysis of 
phophorylated proteins, whereas supernatant in buffer II for Western blot analysis of 
other proteins. Samples homogenized in buffer III were centrifugated at 105,000 g for 
1 h at 4℃ and supernatant was used to determine enzyme activities. Buffer I was 50 
mM Hepes, pH 7.4 with 100 mM NaCl, 1% Triton X-100, 5 mM EDTA, 1 mM 
sodium pyrophosphate, 1 mM sodium orthovanadate, 1 mM NaF, 1 mM 
phenylmethylsufonyl fluoride (PMSF), 10 μg leupeptin/ml, 10 μg aprotinin/ml, 1 μM 
microcystin. Buffer II was 50 mM potassium phosphate buffer, pH 7.8, 0.1% Triton 
X-100, 1.34 mM diethylenetriaminepeantacitic acid, 1 mM PMSF, 10 μg pepstatin 
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A/ml, 10 μg leupeptin/ml, 10 μg aprotinin/ml. Buffer III was 20 mM Tris-HCl, pH 7.4 
with 0.25 M sucrose. Protein concentrations in buffer I were measured with a BCA 
protein assay kit (Pierce Chemical Co., Rockford, IL). Protein concentrations in buffer 
II and III were measured by Lowry’s method (117). 
 
2.4 Blood and Tissue Chemical Analyses 
Plasma total cholesterol (TC), total triglyceride (TG), and non-esterified free fatty 
acids (NEFA) were determined by using Cholesterol E kit, Triglyceride L-type TG H 
kit, and NEFA C kit (Wako Pure Chemical Industries,  Japan),  respectively. 
Cholesterol and triglycerdide of HDL and (V)LDL fractions were measured using a kit 
from Biovision Inc. ( Mountain View, CA). Total lipids of tissues, organs and feces 
were extracted by using the Folch extraction procedure and, resuspended in 1% Triton 
X-100 ethanol (118), and concentrations were determined as indicated above. Tissue 
cholesterol and triglyceride were calculated based on protein concentration or dry 
mass.  
 
2.5 Western Blot Analysis 
Western blot analysis was used to determine protein expression in tissue homogenates 
or cell lysates. Briefly, predetermined amounts of proteins were loaded and separated 
in SDS-PAGE gels, and then transferred to nitrocellulose membranes. Membranes 
were blocked at room temperature for 1 h, and then incubated with appropriate 
primary antibodies overnight at 4℃. Thereafter, the membranes were washed and 
incubated with either anti-mouse or anti-rabbit secondary antibody at room 
temperature for appropriate time. Anti-rabbit IgG HRP was from Bio-Rad 
Laboratories (Hercules, CA), and anti-mouse IgG HRP was from Pierce (Rockford, 
IL). Signals were detected with SuperSignal West Pico Kit (Pierce Chemical Co., 
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Rockford, IL) and exposed to imaging films (Kodak, Rochester, NY) according to the 
manufacturer’s instructions. The source, dilution and preparation of primary 
antibodies are listed in Table 2.2. 
 
2.6 Total RNA Extraction 
Total RNA was extracted from livers or cultured cells using Trizol reagent (Life 
Technologies, Bethesda, Maryland, USA), according to the manufacturer’s 
recommendation. Briefly, 50 mg of frozen liver or about 106 cultured cells were 
transferred to 1ml of Trizol solution and homogenized with a Polytron (Brinkmann 
Instruments, Littau, Switzerland), following phenol-chloroform extraction, and 
precipitation with isopropanol. Precipitated RNA was washed with 75% ethanol. RNA 
pellet was dissolved in DEPC-treated water. RNA concentration was assessed by 
absorbance spectrophotometry, and RNA integrity was confirmed either by 
nondenaturing agarose gel electrophoresis or Agilent Bioanalyzer 2100 (Foster City, 
CA). RNA was stored at -80°C. 
 
2.7 Reverse Transcription and Real Time Quantitative PCR 
One microgram of total RNA was used to synthesize the first strand of cDNA using 
SuperScript III reverse transcriptase (Invitrogen Life Technologies). The ABI Prism 
7700 Sequence Detection System and the SYBR Green Master Mix kit (both from 
Applied Biosystems) was used to detect real-time PCR products from cDNA samples. 
The total volume of reaction mixture was 10 μl (5μl 2× SYBR Green master mix, 0.5 
μl primers (10 μM), 1μl cDNA and 3.5 μl nuclease-free sterile water). PCR was 
performed for 40 cycles at 95°C for 15 seconds and 60°C for 1 minute after initial 
incubations at 95°C for 10 minutes. The specific primers of each gene are listed in 
Table 2.3. The specificity and purity were evaluated by agarose gels. Sample Ct values 
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Table 2.2 Source, dilution and preparation of primary antibodies 
Antibody  Species  Dilution  Buffer1 Source  
CAT  Goat  1:500  5% milk TTBS  
Santa Cruz 
Biotechnology  
(Santa Cruz, CA)  
GPX1 Rabbit  1:5000  5% milk TTBS  
 
Lab Frontier 
(Seoul, Korea) 
  
SOD1 Rabbit  1:5000  5% milk TTBS  
Chemicon 
(Temecula, CA)  
 
SREBP1 Rabbit  1:1000  5% milk TTBS  
Santa Cruz  
Biotechnology  
(Santa Cruz, CA) 
SREBP12 Mouse  1:500  5% milk TTBS  
Gift from Dr. 
Chang ( Dartmouth 
University) 
SREBP2 Rabbit  1:1000  3% milk TTBS  
Santa Cruz 
Biotechnology  
(Santa Cruz, CA) 
SREBP22 Mouse  1:500  5% milk TTBS  
Gift from Dr. 
Chang ( Dartmouth 
University) 
HMGCR Mouse 1:500 3% milk TTBS 
Gift from Dr. 
Chang ( Dartmouth 
University) 
P382 Rabbit 1:1000 3% milk TTBS 
Cell Signaling 
(Beverly,MA) 
 
Phophorylated-
P382 Rabbit 1:1000 3% BSA TTBS 
Cell Signaling 
(Beverly,MA) 
1 
TBS represents Tris buffered saline, pH 7.4, while TTBS represents TBS buffer with 
1% Tween 20.  
2 
Used in related studies which are not shown in this thesis 
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 were normalized to Ct values of mouse 18s rRNA, all of which were calculated from 
two PCR reactions performed in triplicates from each genotype. Relative gene 
induction values were calculated following the manufacturer’s recommendations as 
2△△Ct, (△△Ct= (Ct gene interested of WT-Ct18s of WT )- (Ct gene interested of KO-Ct18s of KO)). 
2.8 Enzyme Activities Analysis 
Acetoacetyl CoA thiolase activity was assayed with 15 μM of Acetoacetyl-CoA 
(AACoA) and 50 μM of CoA in 0.1 M Tris-HCl (pH 8.0), 25 mM MgCl2, 0.5 mM 
DTT, 50 mM potassium chloride. Enzyme activity was monitored by a decrease of 
AACoA at 303nM. The activity was normalized by protein concentration. 
Short-chain 3-hydroxyacyl-CoA dehydrogenase (SCHAD) activity was determined 
spectrophotometrically at 340 nm with the C4 substrates and NADH as the electron 
donor. The final assay mixture contained, in a final volume of 250 ul, 100 mmol/L 
potassium phosphate, pH 6.5, 0.1 mmol/L  EDTA, and 0.1 mmol/L NADH. Buffer 
was warmed to 30℃ and all assays were carried out in Biotek plate reader at 30 °C. 
Samples (1–20 µL, containing 2–10 µg of soluble protein) were added to this mixture 
and the basal rate (for 1–3 min) was determined. The baseline was generally stable and 
showed minimal bias over 10 min. The reaction was initiated by the addition of C4 
substrate with final concentration 50 µmol/L. 
 
2.9 Statistical Analysis 
Values were expressed as mean ± SE. Statistical comparisons between each group 
were performed by using one way ANOVA for repeated measures followed by 
Dennett’s test using SAS software (release 6.11, SAS Institute, Cary, NC). 
Significance was defined as P < 0.05.
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CHAPTER THREE 
ACTIVATION OF CHOLESTEROL BIOSYNTHETIC PATHWAY IN 
CU,ZN-SUPEROXIDE DISMUTASE KNOCKOUT MICE 
3.1 Abstract 
Knockout of superoxide dismutase has been shown to cause abnormal lipid 
distribution in liver and heart (119-121). This study was conducted to investigate the 
role of Cu, Zn superoxide dismutase (SOD1) in lipids metabolism. Wild-type (WT) 
and SOD1 knockout (SOD1-/-) mice at 3 and 9 weeks of age were used to examine the 
phenotype and molecular signal transduction in the regulation of lipids metabolism. 
Interestingly, knockout of SOD1 caused hypercholesterolemia and 
hypotriglyceridemia with abnormal lipid accumulation in liver, heart, kidney, muscle 
and testis. The cholesterol synthetic pathway was consistently activated in SOD1-/- 
mice as indicated by increased mRNA and protein level of related genes at 3 and 9 
weeks of age. Moreover, SOD1-/- had reduced mRNA level of hepatic fatty acid 
synthase and increased hepatic LPL mRNA; at the same time, they had increased 
activities of mitochondria short-chain-3-hydroxyacyl-coenzyme A dehydrogenase and 
thiolase as well as increased plasma ketones level. We observed increased SREBP2 
but decreased SREBP1 protein, which might be responsible for the changes of its 
target genes in SOD1-/- mice. Our data suggest that SOD1 is indispensible in 
maintaining the normal lipid metabolism through, at least in part, the SREBPs 
pathway.  
 
3.2 Introduction 
Cholesterol is an essential structural component of cells as well as a precursor of 
important hormones in animals. The cellular cholesterol level has to be maintained at a 
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steady level to meet the requirement of normal cellular metabolism. This is achieved 
by a feedback regulatory system that senses the level of cholesterol in the ER 
membranes and modulates the transcription of genes encoding enzymes of cholesterol 
biosynthesis and uptake from plasma lipoproteins (122). Therefore, two sources 
provide mammalian cells with cholesterol: receptor-mediated endocytosis of LDL by 
LDL receptor (LDLR) and de novo synthesis from acetyl-CoA by synthetic pathway 
(75). The biosynthesis of cholesterol occurs in the ER, cytosol and microsomes, and is 
catalyzed by specific enzymes. The first related enzyme is HMG-CoA reductase, 
which catalyzes the rate-limted step of cholesterol synthesis. This is an ER 
membrane-spanning enzyme, catalyzing the four-electron reduction of HMG-CoA to 
CoA and mevalonate (MVA), which is then converted to isopentenyl pyrophosphate, 
the building block for cholesterol and nonsterol isoprenoids (123). Many studies have 
been conducted to explore the regulatory mechanisms of this enzyme in vivo as a 
potential target for lowering-cholesterol drugs. HMG-CoA reductase can be 
phosphorylated or dephosphorylated by AMPK and PP2A and it is physiologically 
present in cells in unphosphorylated active form (~30%) and phosphorylated inactive 
form (~70%) (124). The enzymatic inactivation is due to the phosphorylation of the 
serine 871 present in the catalytic domain (102). The existence of HMG-CoA 
reductase in interchangable active and inactive forms provides a mechanism for the 
rapid short-term regulation of the pathway for cholesterol biosynthesis (125). The 
enzyme can also be inactivated by dithiol oxidation, and its activity depends on 
thiol/disulfide oxidation state of the cellular glutathione (126).   
At the transcriptional level, cholesterol biosynthesis is well known to be regulated by 
SREBPs. There are three different SREBPs: SREBP-1a, -1c and -2. SREBP1a and 1c 
are isoforms produced from a single gene by alternate splicing (69). SREBP 2 isoform 
preferentially regulates genes involved in cholesterol homeostasis including all the 
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cholesterol biosynthetic enzymes (127). SREBPs are basic-helix-loop-helix-leucine 
zipper transcription factors synthesized as inactive precursors bound to the membranes 
of the ER (70). In the ER, the C terminus of the SREBP interacts with a protein called 
Scap (SREBP-cleavage activating protein), which functions as a sterol sensor, specific 
to the cholesterol level. (71-74). Another sterol sensor is Insig (Insulin induce gene) 
which is an oxysterol binding protein different from Scap (71). When cells have 
sufficient sterol, Scap and Insig bind their specific sterol, which promote the binding 
of each other and prevent ER exit of SREBP (75, 76). In sterol-depleted cells, Scap 
does not bind to Insig, allowing ER exit of SREBP-Scap via COPII vesicles (73). Scap 
escorts the SREBPs from the ER to the golgi, where they are processed by two 
membrane-associated proteases, the site 1 (S1P) and site 2 (S2P) proteases, which 
release the mature forms of the proteins (77, 78). These transcriptionally active 
fragments of the SREBPs translocate to the nucleus, where they bind to the promoters 
of SREBP target genes and interact with other signaling proteins (79-81).  This 
pathway provides a long-term regulation of cellular cholesterol level and makes cells 
efficiently integrate the signals from different responses at the transcriptional level. 
For example, the binding of ATF6 to SREBP attenuates its transcriptional activity and 
reduces the lipogenic effect of SREBP2 (128). SCF(Fbw7), a ubiquitin ligase, can 
regulate lipid metabolism through the control of the phosphorylation-dependent 
degradation of the SREBPs family  (129). Upstream stimulatory factor (USF) 
directly interacts with SREBPs and synergistically activates the target genes (130).  
SOD1 is the major cellular isoform of superoxide dismutase and catalyzes superoxide 
conversion into hydrogen peroxide, which is then converted into water by catalase or 
glutathione peroxidase 1 (131). SOD1 is located mainly in cytosol, but also found in 
the intermembrane space of the mitochondria  (42). As an important antioxidant 
enzyme, SOD1 protects cells from the damage of superoxide. The SOD1 deficiency 
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results in an increased incidence of pathological changes, such as 
hepatocarcinogenesis, hearing loss, muscle atrophy and others (2-9). As a consequence, 
the lifespan of SOD1 knockout mice is reduced by approximately 30% (52). Basically, 
this phenotype is deemed as the outcome of increased oxidative stress. However, 
SOD1 is also found to play an important role in nucleus as a co-activator of particular 
transcriptional factors. SOD1 enhances the binding of ERα to estrogen response 
element-containing DNA and is required for effective estrogen responsiveness of 
the endogenous pS2, progesterone receptor, cyclin D1, and cathepsin D genes (51). 
SOD1or SOD2 knockout have been reported to cause hepatic lipid accumulation and 
dyslipidemia in mice (132, 133). However, the exact role of SOD1 in lipid metabolism 
has still remained unknown. In the present study we examined the impact of SOD1 
knockout on lipid metabolism in mice, focusing on alterations of hepatic cholesterol 
metabolism. Our data indicate that the hypercholesterolemia, hypotriglyceridemia and 
fatty liver result from the increased biosynthesis of cholesterol which is activated at 
transcriptional level of cholesterol synthetic pathway genes. The results of the present 
study establish a new link between oxidative stress and the regulation of lipid 
metabolism at the transcriptional level. 
 
3.3 Experimental Design 
Chemicals and antibodies.  All chemicals were purchased from Sigma Chemical Co. 
(St. Louis, MO) unless otherwise indicated. Reagents for cholesterol, triglyceride and 
non-esterified fatty acids determination were from Wako Chemicals USA, Inc. 
(Richmond,VA). Antibodies used in this chapter are listed in Table 2.2. Gene 
expression profile was assessed by real time PCR using ABI Prism 7700 Sequence 
Detection System as indicated before. 
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Animals.  The SOD1 knockout (SOD1-/-) and wild-type (WT) mice generated from 
129SVJ x C57BL/6 strain，were generously provided by Y. S. Ho of Wayne State 
University, Michigan  (116). Mice were weaned at 3 weeks of age and fed normal 
diet for 6 weeks based on the design of experiments.  All mice used were male and 
their genotypes were verified by PCR.  
Plasma and tissue lipids measurements.  Total plasma cholesterol, triglyceride and 
non-esterified fatty acids levels were measured by using commercially available kits 
(Wako Pure Chemical Industries). Total cholesterol and triglyceride in HDL and 
(V)LDL lipoproteins were measured by using a kit from Biovision Inc. (Mountain 
View, CA). Tissues or organs were collected from 9 week old mice and were rinsed in 
cold PBS buffer to remove blood, and then homogenized in PBS buffer before lipids 
extraction. The final cholesterol and triglyceride levels were measured as indicated 
previously and normalized based on the protein levels. 
Total RNA extraction, cDNA synthesis and real time PCR.  Total RNA was 
extracted from 50mg frozen liver samples with Trizol reagent. Reverse transcription 
was performed on 1 μg total RNA per sample. Real time PCR was conducted with 
gene specific primers as listed in table 2.3. The generation of specific PCR products 
was confirmed by melting-curve analysis and gel electrophoresis. 
Mitochondria isolation.  Mitochondria were isolated by differential centrifugation 
(10). Livers were finely minced and then homogenized in a 10-ml Wheaton Scientific 
Teflon-to-glass homogenizers in sucrose buffer III. The homogenate was centrifuged 
at 600 g for 10 minutes to remove cell and tissue fragments and cell nuclei, and then 
supernant was transferred into a new tube and spinned at 8,000×g for 15minutes. 
Mitochondrial pellets were washed with the same buffer for 3 times, and then 
resuspended in 600 μl buffer I. Sonication was performed to release the mitochondrial 
protein. 
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Nuclei isolation.  Nuclei were isolated by Dounce homogenization and sucrose 
gradient centrifugation. Whole livers were minced in 5 ml of ice cold buffer A (10 
mM Hepes, pH 7.9; 25 mM KCl; 1 mM EGTA; 1 mM EDTA; 0.32 M sucrose; 0.15 
mM spermine; 0.5 mM spermidine; 1 mM DTT; 0.5 mM PMSF; 0.5 μg/ml leupeptin;  
1 μg/ml aprotinin; 1 μg/ml pepstatin) and homogenized in a 10-ml Potter-Elvehjem 
(Wheaton Science Products, Millville, NJ) Dounce homogenizer. Crude nuclei were 
collected by centrifugation (800×g, 10 min, 4 ℃). The nuclei pellet was diluted with 
2 vol. of buffer B (buffer A with 2 M sucrose) and layered onto buffer B sucrose 
cushions in polyallomer centrifuge tubes. The gradient was centrifuged for 60 min at 
1,00,000×g (Beckman Coulter). The pure nuclear pellet was then resuspended in 2.5 
ml of buffer A, diluted with 5 ml of buffer B, and layered onto a second 3.5-ml 
cushion of buffer B for centrifugation. Nuclei were resuspended and sonicated in 
NP40 buffer with protein inhibitors, and stored in -80℃.  
Western blot analysis. Liver homogenate (30 μg of protein) or nucleus extract (10 μg 
of protein) was used for Western blot analysis as described in the General Material 
and Methods section. Antibodies used in this chapter are listed in Table 2.2.  
 
3.4 Results 
Knockout of SOD1 caused hypercholesterolemia and hypotriglyceridemia in mice.   
At 3 weeks of age, body weight of SOD1-/- was slightly less than that of WT (P = 
0.07). Concentrations of plasma total cholesterol (TC) and non-esterified fatty acids 
(NEFA) in SOD1-/- mice was 59% and 76% higher as compared to WT mice, 
respectively (P < 0.001), while total triglyceride (TG) level was 42% lower (P < 0.001) 
(Table 3.1). Both genotypes had similar concentrations of plasma total protein. 
Therefore, the genotype difference in plasma lipids did not vary by the calculation 
based on either the total plasma volume or total plasma protein levels (Table 3.2). The  
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Table 3.2. Body weight and plasma lipids concentrations of WT and SOD1-/- mice at 
9 weeks of age＃ 
 
 BW(g) TC(mg/dl) TG(mg/dl) NEFA(mg/dl) 
WT 24.92±0.95a§ 176.68±9.63 121.93±18.43 23.01±2.43 
SOD1+/- 23.16±0.70ab 175.13±7.73 118.37±14.95 22.96±1.53 
SOD1-/- 21.64±1.46b 225.33±10.43* 48.61±8.38* 23.74±1.92 
＃All mice (n = 8~12) were males and were fasted for 8 hours before the experiment. 
Blood samples were collected by cardiac puncture into EDTA-coated tubes. Total 
cholesterol, triglyceride and NEFA were measured by using kits from Wako 
Chemicals USA Inc. 
§ Different letters indicate the significant difference between genotypes (P < 0.05). 
Values are mean ±  SE. BW, body weight; TC, total cholesterol; TG, total 
triglyceride; NEFA, non-esterified fatty acids. 
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TC:TG ratio of SOD1-/- mice was 8.2 vs. 2.9 of WT (P < 0.001). There was no 
difference in body weight, TC and TG between WT and SOD1+/- mice, while plasma 
NEFA of SOD1-/- was higher than that of WT mice (P < 0.01). The increase in total 
plasma cholesterol was mainly due to increased high density lipoproteins (HDL), 
while the decreased total plasma triglyceride was due to (V)LDL in SOD1-/- mice, 
although some changes were found in other fractions (Figure 3.1 & 3.2). At 9 weeks 
of age, SOD1-/- was lighter as compared to WT (P < 0.05); SOD1-/- mice had 27% 
higher TC and 61% lower TG in plasma (P < 0.05) as compared to WT, (Table 3.2). 
There was no difference in plasma NEFA between genotypes. The TC:TG ratio of 
SOD1-/- was more than 3 times of WT, 4.51 vs. 1.38, respectively. 
Abnormal lipid profile in tissues and organs in SOD1-/- mice.  The organs or 
tissues weight values were expressed as a ratio according to body weight in 9 week old 
mice (Figure 3.3). Compared to WT, SOD1-/- mice had enlarged livers and spleens, 
and reduced kidney, testis and abdominal fat pad weights (P < 0.05). The 
concentrations of cholesterol in liver, heart and muscle were 52%, 23%, 15%, and 14% 
higher in SOD1-/- than in WT (P < 0.05). SOD1-/- mice also had 225%, 173%, 43%, 
16% more triglyceride in testis, liver, heart and kidney, respectively (P < 0.05) (Figure 
3.4, Figure 3.5), while 30% (P < 0.05) less triglyceride in spleen as compared to WT. 
Elevated hepatic gene expression of cholesterol, but not fatty acids, synthetic 
pathways in SOD1-/-.  Microarrays and real time PCR were used to further explore 
changes in gene expression in the livers of SOD1-/- mice. Microarray results showed 
that, at 9 wk, over 30 genes, which expressions were changed more than two folds, 
were related to lipid metabolism (Figure 3.6). Among these genes, 23 up-regulated 
genes were specifically related to cholesterol synthesis and fatty acids mobilization 
and oxidation, and 8 down-regulated genes, including Fasn, were related to fatty acid 
synthesis. The second largest group changed genes is related to oxidoreductase family.
 32 
 
 
 
 
 
 
 
Figure 3.1. The distribution of cholesterol in HDL and (V)LDL lipoproteins in WT and 
SOD1-/- mice at 3 weeks of age. All mice (n = 6) were male and fasted for 8 hours 
before being sacrificed. Blood samples were collected by cardiac puncture into 
EDTA-coated tubes, and plasma was separated immediately. HDL and (V)LDL 
lipoproteins were analyzed by using a kit from Biovision Inc. Cholesterol of each 
fraction was measured by using kits from Wako Chemicals USA Inc. An asterisk 
indicates the significant difference between genotypes (P < 0.05). HDL, high density 
lipoprotein; (V)LDL, (Very) low density lipoprotein. 
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Figure 3.2. The distribution of triglyceride in HDL and (V)LDL lipoproteins in WT 
and SOD1-/- mice at 3 weeks of age. All mice (n = 6) were male and fasted for 8 
hours before being sacrificed. Blood samples were collected by cardiac puncture into 
EDTA-coated tubes, and plasma was separated immediately. HDL and (V)LDL 
lipoproteins were analyzed by using a kit from Biovision Inc. Triglyceride of each 
fraction was measured by using a kit from Wako Chemicals USA Inc. An asterisk 
indicates the significant difference between genotypes (P < 0.05).   
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Real time PCR was used to confirm these same changes. As indicated in Figure 3.7, 
there was a significant increase of mRNA levels of gene controlling cholesterol 
synthesis, including HMG-CoA synthase (2.9-fold), HMG-CoA reductase (3.1-fold), 
Farnesyl diphosphate synthase (4.6-fold), qualene synthase (4.1-fold), squalene 
epodase (4.7-fold), and lanosterol synthase (4.2-fold) in the liver of 9 week old 
SOD1-/- mice. Similar changes were also observed in 3 week old mice (Figure 3.8). 
Squalene epoxidase was the most changed gene of cholesterol synthetic pathway and 
was increased by 2.9 times in SOD1-/- mice. Consistent with the change at mRNA 
level, the amount of HMG-CoA reductase protein was higher in SOD1-/- mice than 
WT mice as shown in Figure 3.11. In addition, there were a 20% decrease of Fasn 
mRNA and a 60% increase of lipoprotein lipase mRNA in the liver of SOD1-/- mice 
(P < 0.05) as compared to WT mice.  
Increased fatty acid mobilization and oxidation in SOD1-/- mice.  Our previous 
data indicated the increased fatty acid mobilization and oxidation in SOD1-/- mice, 
therefore activities of a few important enzymes were assessed. The activity of 
short-chain 3-hydroxyacyl-CoA dehydrogenase (SCHAD) was significantly higher in 
the mitochondria of SOD1-/- than that of WT mice (P < 0.001) (Figure 3.9), thus 
pointing on possible increased fatty acid oxidation in mitochondria. Moreover, in 
SOD1-/- mice, the activity of acetoacetyl CoA thiolase was 40% higher in 
mitochondria, though 40% lower in cytosol, thus totally not different from WT (Figure  
3.10), and consistent with the increased fatty acid oxidation. The concentration of 
plasma beta-hydroxybutyrate after 8 hours fasting in SOD1-/- was 64% higher than in 
WT (P < 0.001) (Figure 3.11), proving higher fatty acid oxidation rate in SOD1-/- 
mice. 
Increased mature SREBP2 in nuclei may be responsible for the new metabolic 
pattern of SOD1-/- mice.  As shown in Figure 3.12, SOD1-/- mice expressed less  
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Figure 3.9. Effect of SOD1 knockout on hepatic SCHAD activity. Mice (n = 5, male) 
were sacrificed at 9 weeks of age after being fasted for 8 hours. Mitochondria were 
isolated from the fresh liver homogenates by centrifugation in sucrose buffer as 
described previously. The SCHAD activity was measured as stated in Experiment 
design. *indicates the significant difference between genotypes (P < 0.05). 
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Figure 3.10. Effect of SOD1 knockout on hepatic acetoacetyl CoA thiolase activity. 
Mice (n = 5, male) were sacrificed at 9 weeks of age after being fasted for 8 hours. 
Mitochondrial and cytosolic fractions were prepared from the fresh liver homogenates 
by centrifugation in sucrose buffer as described previously. Acetoacetyl CoA thiolase 
activity was measured as stated in Experiment design. *indicates the significant 
difference between genotypes (P < 0.001). 
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Figure 3.11. Concentrations of plasma β-hydroxybutyrate in WT and SOD1-/- mice. 
Mice (n = 5, male) were sacrificed at 9 weeks of age after being fasted for 8 hours. 
Blood samples were collected by cardiac puncture into EDTA-coated tubes, and 
plasma was immediately separated after collection. The concentrations of 
β-hydroxybutyrate were measured as described previously. *indicates the significant 
difference between genotypes (P < 0.001). 
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Figure 3.12. Western blot analysis of SREBP1, SREBP2 and HMG-CoA reductase in 
livers of WT and SOD1-/- mice. Liver samples were collected from male mice (n = 5 
per genotype) at the age of 3 weeks. Mice were fasted for 6 hours before killing. Total 
protein was extracted from livers as described in the text.   
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SREBP1 protein, but much more SREBP2, in both the precursor and the mature 
proteins, when whole-cell lysates were subject to analysis. To further explore SREBPs 
localization, nuclei fractions were used to test the presence of SREBPs. Indeed, mature 
SREBP2 in nuclei of SOD1-/- was about two times of WT, as indicated by Figure 
3.13.  
 
3.5 Discussion 
The most interesting finding from this study is that the knockout of SOD1 causes 
hypercholesterolemia and hypotriglyceridemia in mice. Compared with the WT mice, 
SOD1-/- mice showed increased level of de novo synthesized cholesterol in plasma, 
tissues and organs. The elevated cholesterol level correlated with increased expression 
of cholesterol synthetic pathway genes, increased mobilization, oxidation and reduced 
synthesis of fatty acids. Deletion of SOD1 leads to the energy usage for excessive  
cholesterol synthesis rather than fat accumulation. We hypothesize the priority of 
cholesterol synthesis, as hormones precursor which essential for survival under 
oxidative stress because of SOD1 deficiency, and as new building blocks for the cell 
membranes repair, increasingly damaged because of SOD1 absence. It is worthwhile 
to mention another metabolic symptom caused by over expression of cellular 
antioxidant enzyme, glutathione peroxidase 1, which results in obesity and affected 
glucose metabolism, discovered in our lab (131).  
Superoxide dismutase is responsible for the clearance of toxic superoxide, which is 
also a signaling agent (42). It has been reported that knockout of either cellular SOD1 
or mitochondrial SOD2 increases triglyceride accumulation  in liver and heart 
(119-121), which is consistent with our results. However, Uchiyama et al. (121) did 
not observed the lipid change in the liver of SOD2-/- mice and in the plasma of 
SOD1-/- mice, which had been found by others (119, 120). The difference may  
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Figure 3.13. Western blot analysis of nuclear SREBP2 in livers of WT and SOD1-/- 
mice. Liver samples were collected from male mice (n = 4 per genotype) at the age of 
9 weeks. Mice were fasted for 8 hours before killing. Nuclei were isolated by 
centrifugation in sucrose buffer. The density was measured by software. *indicates the 
significant difference between genotypes (P < 0.05). 
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depend on a different genetic background, in which other antioxidant agents might 
compensate for the loss of target gene. Together, it is clear that SODs could affect 
lipid and energy metabolism as indicated by majority of relevant studies.   
In this study, the symptom of severe dyslipidemia is very striking and indicates a role 
of SOD1 in lipid and energy metabolism, directly or indirectly. Most interestingly, the 
concentrations of cholesterol and triglyceride change in opposite directions in SOD1-/- 
mice at the different age. This phenomenon is a rare case in mammals. The TC:TG 
ratio is maintained in a certain range to meet the needs of extra hepatic tissues and 
organs for lipids. The irregular profile of plasma lipids indicates the abnormal 
distribution of lipids among tissues and organs (136). Elevated plasma cholesterol and 
triglyceride can contribute to many forms of disease, most notably cardiovascular 
disease. The well-known cause of hypercholesterolemia is the compromised ability of 
clearance of LDL lipoprotein in blood. For example, mutations of LDL receptor, 
APOB and PCSK9, which interrupt the uptake of plasma LDL, results in familial 
hypercholesterolemia (61-64). Hypotriglyceridemia has been found in patients with 
acute exercise, autoimmune disease, and subjects consuming conjugated linoleic acid 
(CLA) contained in high fat diet (137-139). 
Endogenous source was responsible for the increased cholesterol in plasma, liver and 
other tissues in SOD1-/- mice, because no dietary cholesterol was consumed by these 
mice, while the cholesterol synthetic pathway was consistently activated as indicated 
by increased mRNA and protein levels of related genes. Under the normal conditions, 
the cellular cholesterol synthesis is strictly regulated based on the cellular cholesterol 
level which is sensed by proteins located on the ER membrane (77, 78, 122). The 
well-known SREBP2 is the master regulator of cholesterol synthesis genes, and is 
activated and translocated into nucleus as a part of transcription machinery when the 
cell is depleted of cholesterol. When the cell is replete with cholesterol, the process of 
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translocation is blocked by the interaction of Scap/Insig (70, 71, 73, 75, 76, 127). The 
mature SREBP2 in nucleus is degraded rapidly by the ubiquitin-proteasome pathway 
(129). Based on the consistent activation of cholesterol synthetic pathway and the 
increased premature and mature SREBP2 protein level, the feed-back regulation 
mechanism appears to be dysfunctional in SOD1-/- model. It is possible that this 
pathway is disrupted at the step of translocation of SREBP2, which normally takes 
place only when cells are depleted of cholesterol. ER membrane is the headquarters 
for sensing cholesterol and housing SREBP2 in cells, and it is also a factory for 
assembling and folding proteins (70, 71, 140). It has been shown that the accumulation 
of aberrantly folded protein or ROS in ER leads to ER stress (141-143). Interestingly, 
SOD1 is required for tolerance of ER stress induced by superoxide accumulation in 
Saccharomyces cerevisiae (144). Further, Ye et al. (2000) reported SREBPs are 
cleaved by proteases induced by ER stress (145). Therefore, the knockout of SOD1 
may lead to the ER stress induced by accumulated superoxide, and, then, ER stress 
promotes the cleavage of SREBP2 which is translocated to nucleus and initiates the 
transcription of its target genes. 
In addition to the increased level of cholesterol, knockout of SOD1 caused the 
reduction of plasma triglyceride, increased plasma NEFA and ketone bodies. And the 
genes coding enzymes for catalyzing these metabolites were demonstrated to have 
corresponding changes at mRNA levels and functional activities as well. Fasn is the 
key enzyme for fatty acid synthesis, which catalyzes the conversion of acetyl-CoA and 
malonyl-CoA, in the presence of NADPH, into long-chain saturated fatty acids (146). 
Thus, the reduced level of Fasn mRNA may indicate the reduced synthesis of fatty 
acid in SOD1-/- mice. Lipoprotein lipase is an enzyme that hydrolyzes lipids in 
lipoproteins, such as those found in chylomicrons and VLDL, into three free fatty 
acids and one glycerol molecule (147).  Compared to the WT mice, knockout of 
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SOD1 significantly increased the LPL mRNA level. This provides a strong evidence 
for the reduced plasma triglyceride and increased plasma NEFA, as it was reported by 
Merkel, et al., (1998) (148). Consequently, largely increased NEFA raise the 
ß-oxidation of fatty acid and the production of ketone bodies. Short-chain 
3-hydroxyacyl-CoA dehydrogenases (SCHAD) resides in the mitochondrial matrix  
and is involved in the mitochondrial ß-oxidation (149). Mitochondrial 
acetoacetyl-CoA thiolase (commonly called ß-Ketothiolase) is an enzyme with a dual 
function in metabolism, which acts in the breakdown of acetoacetyl-CoA generated 
from fatty acid oxidation and regulates production of ketone bodies(150), while 
cytosolic acetoacetyl-CoA thiolase is likely to be involved in the pathway of steroid 
biosynthesis, catalyzing the synthesis of cytoplasmic acetoacetyl-CoA for substrate 
conversion into 3-hydroxy-3-methyglutaryl-CoA (151). All of above reactions are 
reversible, and the exact functions of both enzymes are still uncertain as the outcome 
of deficiency of both is similarly ketosis (152, 153). The changes of these activities in 
SOD1-/- mice indicate increased fatty acid oxidation and ketone bodies production, 
while the mitochondria is one of the targets that are mostly affected by knockout of 
SOD1. It is clear that the knockout of SOD1 increases ROS production and has a 
remarkable impact on the mitochondrial function (9, 154, 155). Mutated human SOD1 
causes a dysfunction of oxidative phosphorylation in mitochondria of transgenic mice 
(154). To compensate the functional loss and meet the normal demand of ATP, it is 
possible that cell accelerates fatty acid oxidation to increase the energy production in 
SOD1-/- mice. PGC1 and PPARγ are important regulators of mitochondria biogenesis, 
which are induced by ROS and also control the antioxidant system in cell (156, 157). 
It is of an interest that neither was affected by the knockout of SOD1 at mRNA level. 
The opposite change of cholesterol and fatty acids in SOD1-/- mice intrigues the 
management strategy of energy balance under the unfavorable conditions. SREBP 
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pathway responds to the oxygen level and regulates sterol synthesis under hypoxia in 
fission yeast (158). The activation of SREBP offers the advantage for survival as 
sterols are the more important precursors of signal agents than energy molecules. It is 
possible that cholesterol synthesis is activated to ensure the adequate substrate for 
hormones synthesis when cells lose the full ability to cope with superoxide and endure 
the oxidative stress. The biosynthetic pathways of cholesterol and fatty acids share the 
same substrate acetyl-CoA in cytosol, but are governed, at least, by the two close 
though different transcriptional factors, SREBP1c and SREBP2 (159). The functional 
change of one of them drastically alters the ratio of cholesterol and fatty acids in liver 
and plasma (160). Therefore, these proteins dictate the direction of energy flow for the 
synthesis of either cholesterol or fatty acids, and the proper SREBPs ratio determines 
the balance of two lipids. Compared with WT, SOD1-/- mice had significantly higher 
SREBP2 and lower SREBP1 level, as indicated by Western blot analysis. This 
strongly suggests that these two proteins are altered by the deficiency of SOD1, 
directly or indirectly, and these changes are responsible to some extent for the 
increased cholesterol and decreased fatty acid biosynthesis. In addition to the fulfilling 
of energy requirement, increased beta oxidation of fatty acids may be considered as a 
secondary response to the activated biosynthesis of cholesterol, providing adequate 
acetyl-CoA and ATP, while ketone bodies, as by-products, are formed in the altered 
metabolic reaction. 
In summary, this study demonstrates that the important role of SOD1 in lipids and 
energy metabolism has multiple physiological and potentially pharmacological 
implications. First, antioxidant enzyme SOD1 affects de novo cholesterol synthesis, 
while its deficiency causes hypercholesterolemia. Our data suggest the SOD1 related 
pathway is a possible in vivo target for regulation of plasma cholesterol, as in vitro 
studies suggest SOD1 inhibits the cholesterol synthesis (161, 162).  Second, SOD1 is 
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important in maintaining the normal function of mitochondria, which is the 
powerhouse of the cell. It is most likely that increased fatty acid oxidation and ketones 
formation result from the functional loss of SOD1, which reminds us of the 
importance of SOD1 in the treatment of mitochondrial related diseases and 
management of mitochondrial biogenesis. Third, it may suggest the new strategy to 
manage the energy balance by SOD1 or other antioxidant enzymes, such as GPX1 
(131). SREBPs mediate the metabolic changes induced by SOD1 deficiency to some 
extent. Cholesterol, synthesized from acetyl-CoA which is also substrate for fatty acid 
synthesis, could be used as a carrier to excrete energy in feces, and it may shed light 
on the treatment of obesity. Finally, the phenotype of the SOD1-/- mice, including 
hypercholesterolemia, hypotriglyceridemia, liver steatosis, and ketosis, offers a 
desirable model for the study of links among antioxidant balance, lipids metabolism 
and obesity. 
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CHAPTER FOUR 
EFFECT OF HIGH FAT DIET ON THE LIPID METABOLSIM IN COPPER, 
ZINC-SUPEROXIDE DISMUTASE KNOCKOUT MICE 
 
4.1 Abstract 
Our previous study showed that the knockout of Cu, Zn superoxide dismutase (SOD1) 
caused disorders in lipid and energy metabolism. Diet is an important factor which 
could influence the metabolism of lipid and energy in vivo. We hypothesized that the 
metabolic changes induced by the knockout of SOD1 depend on the dietary energy, 
and can be reversed by high fat diet. Three-week-old WT and SOD1-/- male mice 
were fed the normal (11% energy by fat) or high fat diet (58% energy by fat) for 6 
weeks. After the feeding period, we examined metabolic changes and signaling 
proteins. Interestingly, we found that high fat diet reduced body weight of SOD1-/- 
mice by 17% and plasma (V)LDL triglyceride by 15% although the plasma total 
cholesterol and total triglyceride, and fecal cholesterol in SOD1-/- mice were not 
significantly affected. High fat diet significantly increased nuclear SREBP1 and 
SREBP2 proteins in both genotypes but did not reverse the changes induced by the 
knockout of SOD1 in mice fed normal diet. Therefore, the metabolic changes in 
SOD1-/- mice did not depend on the dietary energy source. A high fat diet was not 
able to recover the metabolic symptom induced by the knockout of SOD1. 
  
4.2 Introduction 
Obesity is becoming a serious heath problem worldwide. In 2005, the World Health 
Organization reported that more than 400 million adults worldwide were obese (163). 
In industrialized countries overeating of high energy-containing food leads to the 
excess accumulation of body fat, causing metabolic syndrome-related diseases. In 
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obese individuals the elevated level of lipids promotes excessive production of ROS, 
and systemic oxidative stress, which is considered an important pathogenic 
mechanism of obesity-associated metabolic syndrome (164-167). Antioxidant 
enzymes, as a major part of the antioxidant system, protect cells against the damage of 
ROS. However, the roles of antioxidant enzymes in lipid metabolism and in the 
development of obesity largely remain unknown.  
Energy homeostasis is achieved when anabolic and catabolic processes are in balance 
over long intervals (168). Obesity, a result of the continuous positive balance of 
energy metabolism, is characterized by exceedingly increased mass of adipose tissue. 
Adipose tissue has been appreciated as the energy warehouse to accumulate 
triglyceride in hypertrophied adipocytes during periods of caloric excess, but to 
release these lipids for use by the organism during periods of caloric restriction (169). 
Beyond a warehouse of energy storage, adipose tissue is also an important endocrine 
organ, which secrets a variety of bioactive peptides, called adipocytokines (170). The 
dysfunction of adipocytes and adipose tissue belongs to the primary defects in obesity, 
which is caused by the interaction of genetic and environmental factors (171). 
Adipocytes and hepatocytes serve as the primary sites for fatty acids synthesis, which 
are further transported and incorporated into triglyceride in adipocytes (172). This 
process is under the regulation of various transcriptional factors, including SREBPs, 
AMPK, PPAR gamma and XBP (173-176).  
Many diseases, particularly atherosclerotic cardiovascular disease, type 2 diabetes and 
osteoarthritis, are associated with obesity, and dyslipidemia is one of the major 
changes of obesity induced metabolic syndrome (177, 178). Obese persons release 
increased amounts of fatty acid into the circulation, which can be easily taken up by 
the tissues and oxidized in mitochondria (179). The mitochondrion is the major place 
where ROS are formed during the process of respiration (180). The production of ROS 
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is increased when the concentration of circulating fatty acids rises (181, 182). It has 
been shown that the levels of ROS is increased in fatty liver, plasma and adipose 
tissue, along with increased antioxidant enzymes activities in obese subjects (164, 
183). Adipocytokines, such as tumor necrosis factor-α and angiotensinogen, secreted 
from adipose tissue are also able to increase the ROS production and related to the 
oxidative stress (184). More than an outcome of obesity, the increased ROS also could 
affect the physiological reactions. ROS have been proved to act as intracellular second 
messengers, which lead to induction of unique signal transduction pathways (185). 
Production of ROS is increased selectively in adipose tissue of obese mice, 
accompanied by augmented expression of NADPH oxidase and decreased expression 
of antioxidative enzymes. Moreover, NADPH oxidase inhibitor reduces ROS 
production in adipose tissue, attenuates the dysregulation of adipocytokines, and 
improves diabetic condition, hyperlipidemia, and hepatic steatosis (164). Oxidative 
stress impairs glucose uptake in muscle and fat, and decreases insulin secretion from 
pancreatic β cells (186, 187). ROS derived from NADPH oxidase in vascular smooth 
muscle cells are important to vascular remodeling (24). During hypoxia, ROS act as 
signaling elements in human umbilical vein endothelial cells, regulating secretion of 
the proinflammatory cytokines that lead to alterations of endothelial permeability 
(188). 
The antioxidant system, involving antioxidant enzymes and small chemicals, prevents 
the accumulation of ROS. Cu, Zn superoxide dismutase (SOD1) is an important 
cellular enzyme, catalyzing the dismutation of superoxide to hydrogen peroxide, 
which is further cleared by glutathione peroxidase 1 (GPX1) or catalase. Lack of 
SOD1 significantly impairs the cellular antioxidant ability and promotes oxidative 
stress (5, 155, 189). The expressions of these antioxidant genes are regulated by ROS 
mediated by NF-kB, AP-1, AP-2 and Sp1, as well as C/EBP (see review by Miao, 
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2009) (190). Recently, numbers of studies show that PGC1 and Sirt1, which control 
mitochondrial biosynthesis and lipid metabolism, also regulate the expression of 
antioxidant enzymes, including SOD1, SOD2 and GPX1 (191-194). Furthermore, over 
expression of GPX1 causes obesity and related metabolic syndrome in mice, while 
knockout of GPX1 extremely reduces plasma triglyceride in mice fed a high fat diet 
for a prolonged period (131, 195). It has been reported that knockout of either cellular 
SOD1 or mitochondrial SOD2 increases triglyceride accumulation in liver and heart in 
mice (119-121). Taken together, these results strongly suggest that antioxidant 
enzymes play regulatory roles in lipid and energy metabolism. 
Our previous results showed that knockout of SOD1 significantly activated the 
cholesterol synthetic pathway with outcome of hypercholesterolemia. At the same 
time fat synthesis was suppressed while its mobilization and oxidation were increased 
in mice. There processes were mediated at least in part by SREBPs. Considering that 
dietary energy could affect the energy and lipid metabolism, we hypothesized that 
high fat diet might reverse the observed phenotype. This study was conducted to test 
the effect of high fat (coconut butter) diet on the body weight, blood lipids, and signal 
proteins in WT and SOD1-/- mice. Interestingly, high fat diet did not ameliorate the 
loss of body weight and dyslipidemia caused by the knockout of SOD1 although 
signaling proteins, SREBP1 and SREBP2, were remarkably improved. 
 
4.3 Experimental Design 
Chemicals and antibodies. All chemicals were purchased from Sigma Chemical Co. 
(St. Louis, MO) unless otherwise indicated. Reagents for cholesterol, triglyceride and 
non-esterified fatty acids were from Wako Chemicals USA, Inc. (Richmond ,VA).  
Animals and diets. The SOD1 knockout (SOD1-/-) and wild-type (WT) mice, 
generated from 129SVJ x C57BL/6 strain, were generously provided by Y. S. Ho of 
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Wayne State University, Michigan (116). After weaning at three weeks of age, male 
mice were divided into two groups and were fed either a high-fat or a normal diet for 6 
weeks. The content of normal diet is listed in Table 2.1. Coconut butter was used as 
the energy source of the high fat diet. On caloric basis, the high-fat diet consisted of 
58% energy from fat, 27% from carbohydrate, and 15% from protein, whereas the 
normal diet contained 11% from fat, 74% from carbohydrate, and 15% from protein. 
Plasma and fecal lipid measurements.   All mice were sacrificed at 9 weeks of age 
after an 8-hour-fast. Tissues and organs were collected and frozen immediately. Total 
plasma cholesterol (TC), triglyceride (TG) and non-esterified fatty acids (NEFA) 
levels were measured using commercially available kits (Wako Pure Chemical 
Industries). Total cholesterol and triglyceride in HDL and (V)LDL lipoproteins were 
measured by using a kit from Biovision Inc. ( Mountain View, CA). Fecal cholesterol 
was extracted by using Folch method from dried feces and measured by the method 
stated above. 
Nuclei isolation.  Nuclei were isolated by Dounce homogenization and sucrose 
gradient centrifugation as described previously. 
Western blot. Nuclei extract (10 μg of protein) was used for Western blot analysis as 
described in the General Material and Methods. Antibodies used in this chapter were 
listed in Table 2.2.  
 
4.4 Results 
High fat diet did not improve body weight of SOD1-/- mice.  Compared with 
normal diet, high fat diet did not improve the body weight of SOD1-/- mice. SOD1-/- 
mice had 21% less body weight than WT, 17.99±1.11 vs. 22.92±0.45 grams (P < 0.05), 
respectively, after feeding high fat diet for 3 weeks (Table 4.1). The difference 
between genotypes was increased by 38% after an additional 3 weeks’ feeding with 
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high fat diet. Furthermore, compared with normal diet, high fat diet did not result in 
extra gain of body weight in SOD1-/- mice, but adversely reduced the body weight by 
17% (P < 0.05) after 6 weeks’ feeding. The body weight of SOD1-/- mice was 
consistently less than those of WT and SOD1+/- mice, and the trend was not changed 
by the age and diet. There was no difference in body weight between WT and 
SOD1+/- mice on either diet. 
Plasma lipid profile was not affected by high fat diet in SOD1-/- mice. Similar to 
the results of the previous study, severe hypercholesterolemia and hypotriglyceridemia 
were present in SOD1-/- mice fed normal diet at 6wks and 9wks of age as shown in 
Table 4.2. High fat diet did not affect the plasma TC and TG concentrations in 
SOD1-/- mice, compared with the normal diet. However, plasma TC of WT mice was 
increased to a similar level of SOD1-/- mice when high fat diet was consumed. 
Therefore, high fat diet resulted in a 27% increase of plasma TC in WT mice. There 
was no significant difference in NEFA between the genotypes. To further detail the 
changes of lipids in plasma, cholesterol and triglyceride of HDL and (V)LDL were 
measured. As expected, most plasma cholesterol is located in HDL lipoprotein in WT 
and SOD1-/- mice. As shown in figure 4.1, knockout of SOD1 did not change the 
distribution of major cholesterol, as the percentage of HDL-cholesterol in the plasma 
cholesterol pool of SOD1-/- mice was similar to that of WT. Further, there was no 
effect of high fat diet on the cholesterol distribution among lipoproteins in WT or 
SOD1-/- mice, compared to the normal diet. Figure 4.2 shows that the percentage of 
(V)LDL-triglyceride was higher (P < 0.05) in SOD1-/- mice than in WT mice fed 
normal diet at 9 weeks of age, although the total amount was less (P < 0.05). However, 
high fat diet reversed the trend, and reduced the total amount and percentage of 
(V)LDL-triglyceride in the plasma of SOD1-/- mice by about 25% and 15%, 
respectively (P < 0.05), compared to normal diet. 
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Figure 4.1. The percentage of plasma HDL-cholesterol in WT and SOD1-/- mice fed 
normal diet (ND) and high fat diet (HF). All mice (n = 6~10) were male and fasted for 
8 hours before the experiment. Blood samples were collected by cardiac puncture into 
EDTA-coated tubes, and plasma was immediately separated after collection. HDL and 
(V)LDL were separated before the measurement of total cholesterol as described in 
Materials and Methods. 
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Figure 4.2. The percentage of plasma (V)LDL-triglyceride in WT and SOD1-/- mice 
fed normal diet (ND) and high fat diet (HF). All mice (n = 6~10) were male and fasted 
for 8 hours before being sacrificed. Blood samples were collected by cardiac puncture 
into EDTA-coated tubes, and plasma was immediately separated after collection. HDL 
and (V)LDL were separated before the measurement of total cholesterol as described 
in Materials and Methods. *indicates significant differences between genotypes (P < 
0.05). 
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High fat diet reduced the fecal cholesterol in WT but not in SOD1-/- mice. As 
indicated in Figure 4.3, fecal cholesterol of SOD1-/- mice was significantly higher (P 
< 0.05) than that of WT mice fed either normal or high fat diet. Interestingly, high fat 
diet reduced fecal cholesterol of WT, but not SOD1-/- mice, by 30% (P< 0.001), 
compared to normal diet. Therefore, the difference between WT and SOD1-/- was 
amplified by high fat diet. 
Increased nuclear SREBPs proteins were found in WT and SOD1-/- mice fed 
high fat diet. Figure 4.4 shows that high fat diet significantly increased nuclear 
SREBP1 and SREBP2 proteins in both genotypes. Interestingly, nuclear SREBP1 in 
SOD1-/- mice was significantly less than in WT on normal diet, while high fat diet 
minimized the genotype differences although SOD1-/- was still lower. Opposite to 
SREBP1, the level of nuclear SREBP2 was higher in SOD1-/- mice fed either normal 
or high fat diet, but high fat diet significantly enhanced the presence of SREBP2 in 
nuclei of both genotypes with a similar range, compared to normal diet. 
 
4.5 Discussion 
The most significant finding from this study is that high fat diet did not ameliorate the 
loss of body weight and dyslipidemia caused by the knockout of SOD1. Normally 
high fat diet produces the higher body weight and obesity, and affects the 
concentrations of blood lipids in human and animals (196-198). This was observed in 
the WT, but not in SOD1-/- mice. It is obvious that SOD1-/- mice were resistant to the 
high fat diet induced gain of body weight and obesity. Abundant evidence from 
preclinical and clinical studies indicate that fat promotes excess energy intake and 
positive energy balance (199-201). Dietary fat does not promote its own oxidation in 
the body and is stored efficiently, promoting a positive energy balance (202). However, 
the status of energy balance in SOD1-/- mice was not increased by feeding high fat 
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Figure 4.3. Comparison of fecal cholesterol of WT and SOD1-/- mice. Feces was 
collected from 9 week old mice (n = 5) on normal and high fat diet for one week. 
Total lipids were extracted by using Folch method from dried feces. The final 
concentration was calculated based on the total dry weight and the values are 
expressed as mg/g. * the different letters indicate significant differences between 
groups (p < 0.05). 
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Figure 4.4. Western blot analysis of SREBP1 and SREBP2 in livers of WT and 
SOD1-/- mice on normal diet (ND) and high fat diet (HD). Nuclear proteins were 
prepared from fresh livers as described previously. All mice were male (n = 5 per 
genotype) and were sacrificed at the age of 9 weeks after being fasted for 8 hours. 
Western blot was performed as stated in General Material and Methods. 
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diet, and the deficiency of SOD1 interrupts the normal physiological response in mice, 
as inferred from the lower body weight of SOD1-/- mice under the normal 
nourishment in this study and others (52). The knockout or overexpression of the 
antioxidant enzymes has been found to affect the cellular energy homeostasis. The 
deficiency of mitochondria manganese superoxide dismutase causes slow growth and 
fatty liver (119), while over expression of the antioxidant enzyme, glutathione 
peroxidase 1 causes obesity and related metabolic syndrome (131, 203).  
The regulatory mechanism of antioxidant enzymes in controlling energy balance 
might be mediated by ROS. A large amount of ROS are produced by mitochondria 
during cellular respiration. In addition to their deleterious effects, ROS have been 
proven to function as signaling molecules in many processes (185). A hypothalamic 
ROS is required for insulin-induced food intake inhibition, and the pharmacological 
suppression of this insulin-stimulated ROS elevation, either by antioxidant or by a 
NADPH oxidase inhibitor abolishes the anorexigenic effect of insulin (204). ROS also 
affect the mitochondrial biogenesis in cells. It has been shown that ROS is an 
important mediator of mitochondrial biogenesis induced by homocysteine, and that 
antioxidants may block the process (205).   
Based on the concentration of plasma total cholesterol, high fat exerted a stronger 
impact on the cholesterol metabolism in WT than in SOD1-/- mice, possibly because 
there was no capacity for a further increase in the blood of SOD1-/- mice. The 
previous study showed the cholesterol synthetic pathway was highly activated in the 
livers of SOD1-/- mice with increased level of SREBP2, which is the master regulator 
of cholesterol biosynthesis (206). Actually, high fat diet promoted the increased level 
of the nuclear SREBP2 in both genotypes compared with normal diet as indicated by 
Western blot. Therefore, SOD1-/- mice might reach the maximal level of plasma 
cholesterol, thereby excess of endogenous cholesterol was secreted as fecal cholesterol, 
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as indicated by Figure 4.3. High fat diet significantly increased plasma cholesterol as 
well as SREBP2, but reduced the fecal cholesterol in WT mice, in comparison with 
normal diet. Fecal cholesterol is mainly secreted by the gall bladder and the intestine 
in mice (207). All of the fecal cholesterol was endogenous because there was no 
dietary cholesterol in this study. Cholesterol can be re-absorbed with chylomicrons in 
small intestine (208). Therefore, there might be two reasons for the increased plasma 
cholesterol: reduced loss and increased biosynthesis. However, Bosch and co-authours 
showed that the high-fat diet almost doubled fecal neutral sterol excretion with 
diminished cholesterol absorption while did not affect biliary cholesterol secretion 
(209). Satchithanandam et al., (1993) showed reduced cholesterol absorption in rats 
only when fed 24% sesame oil diet, but no effect was observed with 24% coconut oil 
diet (210). Brussaard et al., (1983) showed that fecal excretion of neutral steroids on 
diets differed in type and amount of dietary fat in young healthy persons (211). 
Therefore, the effect of high fat on the fecal loss of cholesterol varies with the types of 
fat and models. It is reasonable to infer that the fecal cholesterol reflects the body 
status of cholesterol, as higher fecal cholesterol in SOD1-/- was always observed. As 
for the potentially increased biosynthesis of cholesterol induced by high fat diet, the 
SREBP2 mediated pathway could be considered as the major mechanism. Generally, 
SREBP2 controls the cholesterol synthesis by a feedback mechanism based on the 
cellular cholesterol level to meet the requirement of normal physiological reactions 
(77, 78, 122). Consistent with our results, diet with high saturated fat significantly 
increased hepatic total cholesterol contents via enhancing the activity and mRNA 
expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase with increased 
SREBP2 in mice, which could be alleviated by antioxidant compounds, as reported by 
Lin et al., (2008) (212). Dietary fat elevates the ROS production and increases 
oxidative stress (181, 182, 213). Further, oxidative stress induced by different factors, 
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such as virus and oxidant substrates, has been shown to activate the SREBPs pathway 
(214, 215). Therefore, compared to the normal diet, high fat diet increased the mature 
SREBP2, while the knockout of SOD1 showed an additional effect in this study. 
In terms of plasma triglyceride, high fat diet did not increase the concentration in 
SOD1-/- mice. On the normal diet, SOD1-/- mice had only about 40% plasma 
triglyceride of the WT mice. However, there was a decrease of plasma triglyceride in 
WT fed high fat diet, similar to the phenomenon observed by Fearnside et al., (2008) 
in C57BL/6 strain mice (198), from which our lines were developed. There might be a 
relevant metabolic adjustment to the high fat intake with regard to plasma triglyceride, 
which is specific to the genetic background. Nevertheless, we observed a significant 
increase of mature SREBP1 in both genotypes under the high fat feeding, compared 
with normal diet. SREBP1 is an important transcriptional factor for the regulation of 
fatty acid synthesis. High fat diet has been shown to increase hepatic triglyceride via 
enhancing the activity and mRNA expression of malic enzyme and Fasn, mediated by 
SREBP1 (202, 212). The lower level of SREBP1 in SOD1-/- mice accounts for, at 
least partially, the lower level of triglyceride as discussed elsewhere (159). It seems 
that the knockout of SOD1 has an effect on the SREBP1 which could not be reversed 
by the high fat diet. However, energy deficiency or fasting suppresses the expression 
of SREBP1, while feeding reverses the change (216, 217). The increased 
accumulations of subsarcolemmal mitochondria in SOD1-/- mice indicate the 
metabolic adaptation to the mitochondrial dysfunction and reduced biogenesis (9). 
Therefore, there might be an energy deficient condition in SOD1-/- mice which was 
slightly improved by the high fat diet. 
In conclusion, the knockout of SOD1 interrupted the normal metabolic response to 
high fat diet in mice. There was no positive effect on body weight and plasma lipids of 
high fat diet in SOD1-/- mice although nuclear SREBP1 and SREBP2 were increased 
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remarkably, compared to normal diet. The results indicate that SOD1 is essential for 
the SREBPs-mediated process, which could lead to future phenotype changes. 
Multiple adaptive mechanisms could be involved in these processes, which together 
provide the basis for the regulation of energy homeostasis and lipid metabolism with 
altered energy intake in SOD1-/- mice. 
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CHAPTER FIVE 
EFFECT OF DIETARY COPPPER ON THE METABOLIC 
ABNORMALITIES IN COPPER, ZINC SUPEROXIDE DISMUTASE 
KNOCKOUT MICE 
5.1 Abstract 
Our previous studies showed that the knockout of SOD1 caused severe dyslipidemia 
in mice. Cu deficiency occurs in SOD1-/- mice，while Cu deficiency-induced 
hypercholesterolemia in mammals has been documented for decades (ref. 52, 103 and 
107). This study was conducted to test our hypothesis that dietary Cu might counteract 
the metabolic changes induced by the knockout of SOD1. Three-week-old WT and 
SOD1 male mice were fed Cu deficient (less than 1 ppm), normal (11ppm) and excess 
(110 ppm) diet for 6 weeks. We investigated and compared the metabolic changes of 
WT and SOD1-/- mice induced by Cu deficient and Cu excess diet with normal diet as 
control. We found that dietary Cu deficiency elevated plasma cholesterol of WT mice, 
which is comparable to that of SOD1-/- mice, but did not affect the concentrations of 
blood lipids in SOD1-/- mice. Dietary Cu deficiency elevated (V)LDL cholesterol 
while SOD1 deficiency reduced plasma triglyceride and increased hepatic cholesterol 
and triglyceride. Cu excess diet was only found to reduce hepatic triglyceride in terms 
of metabolic changes in this study with no effect on plasma cholesterol and 
triglyceride as well as hepatic cholesterol. We also found that the expression of SOD1 
and catalase proteins negatively correlated to the dietary Cu in WT mice. SREBPs 
proteins were remarkably changed, partially explaining the alterations of phenotype. 
Therefore, excess of dietary Cu supplementation was unable to recover the defects of 
SOD1 deficiency despite of the similarities of symptoms in regard to Cu and SOD1 
deficiency.  
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5.2 Introduction 
The knockout of Cu, Zn superoxide dismutase (SOD1) causes severe dyslipidemia and 
metabolic syndrome in mice as demonstrated in our previous studies and others (9, 
121). It also has been suggested that Cu deficiency gives rise to hypercholesterolemia 
in mammals (103-106). Cu deficiency decreases the SOD1 activity while the genetic 
loss of SOD1 reduces Cu concentration in organs and tissues (52, 106). However, it is 
still unknown whether the nutritional Cu supplementation could reverse the metabolic 
changes caused by the genetic loss of SOD1. 
SOD1 catalyses the dismutation of superoxide radicals to molecular oxygen and 
hydrogen peroxide, and the latter is converted into water by catalase or glutathione 
peroxidase 1 (131, 218). SOD1 is a dimer, which is located in intracellular 
compartments, including the cytosol, nucleus, lysosome and mitochondrial 
intermembrane space in all eukaryotes (42, 219). Each subunit of SOD1 contains one 
Cu and one Zn atom. Cu is essential for catalysis, and reversibly oxidized and reduced 
by successive encounters with superoxide radicals to yield dioxygen and hydrogen 
peroxide, while Zn mainly serves as a structural purpose in addition to a less catalytic 
role (220). Adequate cellular Cu is essential for the formation of active SOD1 from its 
apoprotein which is newly synthesized. Cu deficiency significantly reduces the 
activity of SOD1 in tissues and organs when the dietary supplementation is not met 
(106, 221). 
Coper deficiency as a cause of hypercholesterolemia has been documented decades 
ago. Copper, an essential nutrient, has to be obtained from the diet to support normal 
physiological needs. Otherwise Cu deficiency occurs and causes the metabolic 
alterations, including hypercholesterolemia and lipid disorders (103-106). 
Hypercholesterolemia is a condition characterized by very high levels of cholesterol in 
the blood, which may cause many forms of disease, most notably cardiovascular 
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disease (60). Copper deficiency induces hypercholesterolemia with 30 to 40% 
increases of plasma total cholesterol by most studies (103, 104, 107). HDL and LDL 
cholesterol, triglyceride in rats are consistently elevated by Cu deficiency, while 
VLDL cholesterol varies between studies (103, 108, 109). But Cu deficiency reduces 
cholesterol deposition in livers of rats (108, 110). However, hepatic 
3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase activity is increased 
by Cu deficiency, which catalyzes the rate-limiting step of cholesterol biosynthesis; 
the increased synthesis is responsible for the high net efflux of cholesterol from liver 
to plasma in Cu deficient rats (111). Hepatic fatty acid synthase is also induced by Cu 
deficiency in rats (112). The degradation and secretion of cholesterol could also affect 
the cholesterol status in bodies, but unlikely account for the Cu deficiency-induced 
hypercholesterolemia based on the studies with radio labeled cholesterol in Cu 
deficient rats (103, 113). On the other end, the excess Cu could reduce the hepatic and 
plasma cholesterol. In Wilson disease, elevated hepatic Cu results in the development 
of liver pathology (114). Most importantly, high Cu suppresses the transcription of 
HMG CoA reductase in spite of the increased SREBP2 in liver of the mouse model of 
Wilson disease (115). And this model also shows a 3.6-fold decrease of VLDL 
cholesterol in serum and a 33% decrease of liver cholesterol (115). Together, Cu has a 
significant impact on cholesterol metabolism. 
The knockout of SOD1 significantly increases plasma cholesterol, but decreases 
triglyceride with abnormal lipid deposition in liver, kidney and heart, as shown in 
previous studies (9, 121), which is similar to the Cu deficiency induced lipids disorder. 
Further, both the knockout of SOD1 and Cu deficiency affect mitochondrial function 
and metal homeostasis (9, 48, 222, 223). Considering that SOD1 is the major Cu 
contained protein (52), it is possible that the phenotype of SOD1-/- mice may results 
from the Cu deficiency. On the contrary, SOD1 may mediate the Cu deficiency 
 72 
 
induced metabolic changes as Cu deficiency-reduced the SOD1 activity (106, 221). To 
test our hypothesis that dietary Cu might alter the metabolic abnormalities caused by 
the knockout of SOD1, WT and SOD1-/- mice were fed diets with different levels of 
Cu. And the metabolic changes and signaling proteins were monitored. Interestingly, 
Cu deficiency caused hypercholesterolemia in WT mice, while excess Cu diet had 
only a partial alleviation of the metabolic changes in SOD1-/- mice. The regulatory 
proteins, SREBP1 and SREBP2, were significantly affected by the level of dietary Cu. 
These results suggest that dietary Cu supplementation could not effectively reverse the 
physiological changes in the subjects with the genetic loss of SOD1.  
 
5.3 Experimental Design 
Chemicals and antibodies. All chemicals were purchased from Sigma Chemical Co. 
(St. Louis, MO) unless otherwise indicated. Reagents for cholesterol, triglyceride and 
non-esterified fatty acids were from Wako Chemicals USA, Inc. (Richmond ,VA).  
Animals and diets. SOD1-/- and WT mice, generated from 129SVJ x C57BL/6 strain, 
were generously provided by Y. S. Ho of Wayne State University, Michigan (116). 
After weaning at 3 weeks of age, male mice were subjected to Cu deficient (CD, no 
Cu added) diet, normal (ND, supplemented with 11ppm) diet or Cu excess (HC, 
supplemented with 110ppm) diet for 6 weeks. The complete ingredients of normal diet 
is listed in Table 2.1. The Cu level was fulfilled with the supplementation of 
CuSO4.5H2O into the diet. 
Plasma and hepatic lipids measurements. Plasma was collected from the tail at 6 
weeks old mice for monitoring plasma cholesterol and triglyceride levels. Mice were 
sacrificed at 9 or 12 weeks of age after an 8-hour-fast, and tissues and organs were 
collected and frozen immediately. Total plasma cholesterol, triglyceride and 
non-esterified fatty acids levels were measured using commercially available kits 
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(Wako Pure Chemical Industries). Total cholesterol in HDL and (V)LDL lipoproteins 
was estimated by using a kit from Biovision Inc.( Mountain View, CA). Liver 
cholesterol and triglyceride were extracted by Folch method and measured by the 
method stated above. 
Total superoxide dismutase activity assay. Liver samples were homogenated in 
50mM PBS buffer (pH 7.4) containing 0.1% Triton X-100 and 1.34 mM 
diethylenetriaminepeantacitic aicd. The total activity was determined using a 
water-soluble Formazan dye kit (Dojindo Molecular Technologies, Gaithersburg, MD). 
Enzyme unit was defined as the activity needed to inhibit 50% 
2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium mono- 
sodium salt reduction.  
Nuclei isolation. Nuclei were isolated by Dounce homogenization and sucrose 
gradient centrifugation as described previously.  
Western blot. Liver homogenate or nuclei extract (10 μg of protein) was used for 
Western blot analysis as demonstrated in the General Material and Methods section. 
Antibodies used in this chapter were listed in Table 2.2.  
  
5.4 Results 
The levels of dietary Cu did not affect the body weight of SOD1-/- mice. Table 5.1 
shows that the body weight of SOD1-/- mice was not affected by the levels of dietary 
Cu after 3 or 6 weeks of feeding. Compared with ND, either CD or HC did not 
increase the difference in body weight between WT and SOD1-/- mice. Although all 
mice had a similar body weight at the beginning of the experiment, at 9wk of age, 
SOD1-/- mice weighed 80%, 77% and 82% of WT mice on CD, ND and HC, 
respectively. The difference between genotypes reached the significant level (P < 0.05) 
at 6wk of age. CD insignificantly reduced body weight of WT mice, while HC  
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insignificantly increased body weight of SOD1-/- mice (P > 0.05). Different Cu levels 
did not significantly influenced body weight of WT and SOD1+/- mice. 
Cu deficient diet caused hypercholesterolemia in WT mice, similar to the 
phenotype of SOD1-/- mice. As shown in Table 5.2, CD had a stronger effect on the 
concentrations of plasma lipids than Cu excess diet. Specifically, CD increased plasma 
TC in WT and SOD1+/- mice by 11% and 18%, respectively (P < 0.05), but not in 
SOD1-/-, compared to normal diet at 6wk. However, these changes were not observed 
at 3wk in both WT and SOD1+/- mice. CD also did not affect the concentrations of 
plasma TC in SOD1-/- mice. HC diet did not influenced plasma TC level in WT mice, 
while insignificantly reduced its level in SOD1-/- mice. Neither CD nor HC 
significantly affected the levels of plasma TG in WT and SOD1-/- mice, compared to 
ND. Even after 12 weeks on HC, there was only a subtle decrease of plasma TC in 
SOD1-/- mice (Figure 5.1). However, there was a dose dependent relation between 
dietary Cu level and plasma TG level (P < 0.05) in SOD1-/- mice. In regard to NEFA, 
CD showed negative effects in all genotypes, compared to ND. The most decrease in 
NEFA was observed in WT mice (60%, P < 0.05), and the least in SOD1+/- (21%, P < 
0.05). No effect of HC on NEFA was found among the genotypes, compared with ND 
control. The distribution of cholesterol among the lipoproteins was measured to 
specify the profile of plasma lipids. Figure 5.2 shows that the levels of 
HDL-cholesterol of WT and SOD1-/- mice on CD were similar. CD did not affect the 
lipoprotein cholesterol in SOD1-/-, compared with ND. However, compared to 
SOD1-/- mice, CD led to a higher level of (V)LDL cholesterol in WT mice (P < 0.05), 
although the total cholesterol in plasma between them was not different.  
Cu excess diet alleviated the fatty liver of SOD1-/- mice.  As shown in Figure 5.3, 
SOD1-/- mice had a large amount of cholesterol in liver, and the phenomena did not 
depend on the diets. However, CD increased the hepatic cholesterol in SOD1-/- mice  
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Figure 5.1. Plasma total cholesterol of WT and SOD1-/- mice after 12 weeks of 
feeding Cu excess and normal diet. Mice (n = 5) were fed experimental diets for 12 
weeks after weaning at 3wk. Blood samples were collected from hearts with 
anti-coagulant EDTA, and plasma was immediately separated. All mice were male and 
fasted for 8 hours before the experiment. Total cholesterol was measured by using a 
kit from Wako Chemicals USA Inc. *different letters mean the significant difference 
between groups within the column (P < 0.05). 
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Figure 5.2. Distribution of plasma cholesterol in WT and SOD1-/- mice after 6 weeks 
of feeding Cu deficient diet. Mice (male, n = 7~10) were fed experimental diets for 6 
weeks after weaning at 3wk. Blood samples were collected by cardiac puncture into 
EDTA-coated tubes, and plasma was immediately separated after collection. HDL and 
(V)LDL was separated before the measurements of total cholesterol as described in 
General Material and Methods. *indicates the significant difference between 
genotypes (P < 0.05). 
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Figure 5.3. Effect of dietary Cu on hepatic cholesterol in WT and SOD1-/- mice. 
Livers were collected from 9 week old mice (n = 7~10 per genotype) after 6 weeks of 
feeding different diets. Total liver lipids were extracted by using Folch method. 
Cholesterol was measured by using a kit from Wako Chemicals USA Inc. All mice 
were male and fasted for 8 hours before being killed. The cholesterol concentrations 
were expressed based on the total protein concentrations. * The different letters 
indicate the significant differences between groups (p < 0.05). 
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(P < 0.05), but not in WT mice. Moreover, HC did not show any impact on hepatic 
cholesterol in both genotypes. Figure 5.4 indicats that the hepatic triglyceride of WT 
and SOD1-/- mice was strongly affected by experimental diets. SOD1-/- mice 
displayed severe fatty liver and the symptoms were alleviated by the increased dietary 
Cu. However, both CD and HC reduced hepatic triglyceride (P < 0.05) in the WT mice, 
compared to ND, while CD had the strongest effect. 
Cu deficiency reduced the total SOD activity in WT mice. As expected, the 
knockout of SOD1 caused the major loss of total SOD activity. Compared with ND, 
CD reduced the total SOD activity for about 43% in WT mice, while HC did not show 
a significant effect (Figure 5.5). However, the SOD1 protein in WT was negatively 
correlated with the Cu level, while Cu deficiency elevated and high dietary Cu 
reduced the total SOD1 protein (Figure 5.6). Also, dietary Cu caused a dose-dependent 
decrease of catalase protein, but no effect on GPX1 protein was observed in both 
genotypes. 
Effects of dietary Cu on SREBP1/2, and HMGCR in the livers of the WT and 
SOD1-/- mice. Results of Western blot (Figure 5.6) show that SREBP1 was decreased 
in WT and increased in SOD1-/- mice by CD, compared to ND control, while HC had 
similar but stronger effects on SREBP1. With comparison to ND, SREBP2 was 
increased in WT but decreased in SOD1-/- mice by CD.  HC diet reduced SREBP2 in 
both genotypes, but its level in SOD1-/- mice was still higher. Interestingly, HMGCR 
was higher in SOD1-/- than in WT mice, regardless of which diet was consumed. 
However, HC led to a higher level of HMGCR protein in both genotypes, compared to 
CD and ND.  
 
5.5 Discussion 
In the present study, we demonstrated that the excess of dietary Cu did not completely 
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Figure 5.4. Effect of dietary Cu on hepatic triglyceride in WT and SOD1-/-mice. Mice 
(n = 7~10 per genotype) were weaned at 3 weeks of age and fed Cu deficient diet, 
normal diet, and Cu excess diet for 6 weeks. All mice were male and fasted for 8 hours 
before the experiment. Total lipids were extracted from livers by using Folch method. 
Triglyceride was measured by using a kit from Wako Chemicals USA Inc. The 
concentrations are expressed based on the protein concentrations. * The different 
letters indicate the significant differences between groups (p < 0.05). 
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Figure 5.5. Effect of dietary Cu on total SOD activity in livers of WT and SOD1-/- 
mice.  Mice (n = 7~10) were weaned at 3 weeks of age and fed Cu deficient diet 
(CD), normal diet (ND), and Cu excess diet (HC) for 6 weeks. All mice were male and 
fasted for 8 hours before the experiment. Total proteins were prepared from livers 
before the analysis of SOD activity as described previously. * The different letters 
indicate the significant differences between groups (p < 0.05). 
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Figure 5.6. Western blot analysis of SREBP1, SREBP2, HMGCR, SOD1, CAT and 
GPX1 proteins in livers of WT and SOD1-/- mice. Mice were weaned at 3 weeks of 
age and fed Cu deficient (CD), normal (ND), and Cu excess (HC) diet for 6 weeks. All 
mice were male and fasted for 8 hours before the experiment. Liver homogenates (for 
HMGCR, SOD1, catalase and GPX1) or nuclear proteins (for SREBP1 and SREBP2) 
were prepared from livers before running gel as described previously. The antibodies 
used are listed in Table 2.2. 
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restore the metabolic changes caused by the knockout of SOD1, although some 
benefits were observed. The phenotypes of Cu deficient mice and SOD1-/- mice were 
similar but not exactly the same. We found that, in SOD1-/- mice, dietary Cu did not 
affect body weight, plasma TC and TG concentrations, while Cu deficiency increased 
hepatic cholesterol and triglyceride, and Cu excess diet reduced the hepatic 
triglyceride but not cholesterol levels. Cu deficiency elevated (V)LDL cholesterol in 
WT mice as reported (108), which was different from SOD1-/- mice. SREBP2 might 
mediate the cholesterol biosynthesis in Cu deficient WT mice as well as in SOD1-/- 
mice. The level of hepatic SOD1 protein in WT was adversely correlated with dietary 
Cu level, while total activity was reduced if Cu deficiency existed, in agreement with 
results reported previously (106, 221) . 
Compared with Cu deficiency in WT, the knockout of SOD1 caused more severe 
metabolic changes in mice. It has been established previously that Cu 
deficiency-caused hypercholesterolemia in rats (103, 104, 107) and in mice (106). The 
increased HMG CoA reductase activity, induced by dietary Cu deficiency, accounts 
for the elevated level of cholesterol in blood (111). Further study indicates that Cu 
deficiency increased hepatic GSH, which activates HMG-CoA reductase activity, and 
hypercholesterolemia is abolished by the suppression of GSH (107). However, the 
knockout of SOD1-/- does not affect the basic level of hepatic GSH in mice (224, 225). 
In this study, the level of proteins of HMG-CoA reductase, and its transcriptional 
factor, SREBP2, were also increased in WT mice on CD although the reductase 
activity was not examined. In SOD1-/- mice, hepatic HMG CoA reductase was 
increased at both mRNA and protein levels, as well as SREBP2, which level was also 
remarkably increased. These data suggest that the Cu deficiency and the knockout of 
SOD1 could alter cholesterol biosynthesis at least on the transcriptional level. We also 
found that the knockout of SOD1 eventually led to the increased level of hepatic 
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cholesterol as a result of its increased biosynthesis, while WT mice on Cu deficient 
diet did not show any similar increase of hepatic cholesterol. Our data are in 
agreement with previously reported findings of others (108, 110, 111).  
Compared with the WT mice on ND, dietary Cu deficiency did not affect plasma 
triglyceride, but reduced hepatic triglyceride, while the knockout of SOD1 
significantly reduced plasma triglyceride but increased hepatic triglyceride. As shown 
by Uchiyama et al., (2006), the knockout of SOD1 does impair the secretion of 
lipoprotein from the liver as the degradation of ApoB is promoted, which is 
responsible for carrying cholesterol to tissues (121). SREBP1 is a transcriptional 
factor which could activate the transcription of lipogenic genes, including fatty acid 
synthase (226). Interestingly, either Cu deficiency or SOD1 knockout reduced 
SREBP1 protein, while Cu deficiency reversed the decrease of SREBP1 caused by 
SOD1 deficiency in the mouse model. It is possible that the reduced triglyceride in 
plasma or liver caused by Cu deficiency or the knockout of SOD1 resulted from the 
loss of regulation of SREBP1. However, the increased SREBP1 level in SOD1-/- mice 
on CD and HC remains a mystery as there was no corresponding metabolic change 
observed. Moreover, hepatic fatty acid synthase was found to be induced by Cu 
deficiency in rats (112, 227). 
Excess dietary Cu could not counteract the effects caused by the knockout of SOD1 in 
mice. We hypothesized that the phenotype of SOD1-/- mice might result from the Cu 
deficiency, because hepatic Cu is reduced by 47% in SOD1-/- mice (52). Excess of 
dietary Cu did not improve body weight, plasma lipid concentrations and hepatic 
cholesterol, but reduced hepatic triglyceride in SOD1-/- mice. We found that the 
excessive supplementation of Cu increased SREBP1 but reduced SREBP2 in SOD1-/- 
mice, though both proteins were more abundant in SOD1-/- than in WT on the same 
diet. The decreased SREBP2 protein by the diet was not sufficient to affect the plasma 
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and hepatic cholesterol. It is obvious that excess dietary Cu reversed the changes of 
SREPB1 induced by the knockout of SOD1. However, plasma triglyceride was only 
slightly increased, while hepatic triglyceride was significantly decreased in SOD1-/- 
mice consuming an excess of Cu. It is not surprising because the transcription activity 
of SREBP1 is modified by many factors, such as phosphorylation and sumoylation 
(228, 229).  
SOD1 apoprotein is not a decisive factor in cholesterol biosynthesis. An interesting 
observation from this study was that Cu deficiency reduced total SOD activity but 
induced SOD1 protein, while Cu overdose reduced its protein expression. The loss of 
total SOD activity in SOD1-/- mice suggests that SOD1 accounts for the major activity 
in WT mice, as reported by Lei, et al. (2006) (225). Cu deficiency induced the 
oxidative stress because of decreased SOD1 activity (230, 231). The expression of 
SOD1 is under the regulation of NF-kB, AP-1, AP-2, Sp1, and C/EBP transcription 
factors, which are responsive to ROS-induced stress (see reviewed by Miao, 2009) 
(190). Therefore, SOD1 expression is induced as a result of oxidative stress caused by 
Cu deficiency. Similarly, the Cu excess diet maximizes the antioxidant ability of 
SOD1 and therefore reduces protein expression. Another explanation for the increased 
SOD1 in mice on Cu deficient diet is that the enzyme degradation is decreased. SOD1 
stability is governed by post-translational modification factors that target the SOD1 
disulfide, but oxidation of the disulfide in vivo depends on Cu proteins which could be 
blocked by Cu deficiency (232). Therefore, dietary Cu deficiency stabilizes SOD1 for 
accumulation and excess Cu promotes its degradation in cells. The increased level of 
SOD1 protein in WT mice with hypercholesterolemia is very interesting, because it 
suggests that SOD1 protein itself, at least apoprotein, is not a decisive factor in 
cholesterol metabolism elevated by SOD1 deficiency. This finding may help to 
exclude the possibility that the SOD1 apoprotein is directly involved the regulation of 
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cholesterol metabolism.  
Taking together, our results suggest that dietary Cu could not fully counteract the 
metabolic changes induced by the knockout of SOD1 in spite of the similarities 
between symptoms induced by the Cu deficiency and genetic SOD1 deficiency in 
mice. Hypercholesterolemia is the shared phenotype, while the regulatory mechanism 
might be different. The significance of this study for clinical treatment and therapy of 
lipids disorder is that the nutritional interference of Cu supplementation may not be 
adequate for the genetic loss of SOD1 and the SOD1 apoprotein may not be a useful 
candidate for the treatment of hypercholesterolemia. 
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CHAPTER SIX 
EFFECT OF REACTIVE OXYGEN SPECIES ON THE ELEVATED 
CHOLESTEROL BIOSYNTHESIS IN COPPER, ZINC SUPEROXIDE 
DISMUTASE KNOCKOUT MICE IN VIVO AND IN VITRO 
6.1 Abstract 
Our previous studies show development of severe hypercholesterolemia and increased 
biosynthesis of cholesterol in SOD1-/- mice. Here we hypothesized that reactive 
oxygen species (ROS) were primary factors in regulation of cholesterol biosynthesis 
which affect plasma cholesterol. By using diquat（DQ） as a superoxide generator, we 
examined the impact of ROS on cholesterol biosynthesis in mice and cultured cells. 
Interestingly, significant increases, of 23% and 29%, of total plasma cholesterol were 
observed within two hours in mice injected with DQ dose of 10mg/kg BW and 
30mg/kg BW, respectively. We also found that HMG CoA reductase and squalene 
epoxidase mRNA levels were elevated by 18% and 13%, respectively, compared with 
control. However, at 6 hours after treatment, the mRNA levels were reduced, and 
plasma cholesterol concentrations of mice injected with 30mg/kg BW were decreased. 
In treated mice, the mRNA and protein levels of transcriptional regulator, SREBP2, 
were elevated at early stage. HepG2 cells showed a similar response to DQ treatment 
with increased mRNA levels of HMGCR. In conclusion, ROS may play an important 
role in regulation of cholesterol biosynthesis, and there is a possibility that this 
regulation is mediated by SREBP2. These findings suggest the potential clinical usage 
of ROS generator or scavenger to interfere with problems related to cholesterol 
biosynthesis. 
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6.2 Introduction 
ROS, including superoxide anion ( .2O
 ) and hydrogen peroxide (H2O2), are molecular 
oxygen metabolites, which are produced during the process of respiration in 
mitochondria as well as other cellular reactions. ROS have been traditionally regarded 
as toxic by-products of metabolism with the potential to cause damage to lipids, 
proteins, and DNA (233). However, recent studies have demonstrated that ROS 
actively participate in a diverse array of biological processes and many functions as 
cellular signaling molecules. However, the role of ROS in the cholesterol metabolism 
remains uncertain.  
Cellular ROS are formed in both enzymatic and nonenzymatic reactions. More than 
just by-products of mitochondria biogenesis which could be affected by the energy 
substrate, the production of mitochondrial ROS can be induced by many stimuli, such 
as tumor necrosis factor (TNF)-α , interleukin (IL)-1β  and radiation (22, 179, 234, 
235). The ER and peroxisomes are also important sources of cellular ROS, which are 
abundant in membrane-associated oxidoreductases responsible for metabolizing drugs 
or fatty acids (236, 237). Other enzymes, including xanthine oxidase and NADPH 
oxidase, also affect the local as well as the total levels of ROS in cells upon different 
stimuli (238, 239). Therefore, many processes may affect the cellular redox 
microenvironment.  
To protect organisms from the potential damage of ROS, cells develops specific 
cellular antioxidant system able to scavenge ROS and converts potentially toxic 
molecules into water and others. However, ROS are also essential for the maintenance 
of normal biological processes and enable cells to adjust to the changed environment 
or respond to the extracellular stimulus. Early studies show that hydrogen peroxide 
plays an insulin-like effect on glucose transport and oxidation, and enhances lipid 
synthesis from glucose in adipocytes (19, 20). Mitogen-activated protein kinase 
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(MAPK) signaling pathways are well known to be activated by ROS-induced 
phosphorylation of downstream proteins, ERK, JNK and p38, as widely observed 
earlier (21). It has been suggested that mitochondrial ROS are involved in the process 
of apoptosis induced by TNF-α , IL-1β , while mediate the hypoxia-induced gene 
transcription (22, 23). ROS derived from NADPH oxidase in vascular smooth muscle 
cells mediate the vascular remodeling (24). Recently, protein tyrosine phosphatase-1B 
(PTP1B) has been identified as a ROS-responsive protein, which could be directly 
oxidized and inactivated by superoxide and hydrogen peroxide (25, 26). As PTP1B is 
a key regulator of multiple signaling pathways downstream of receptor tyrosine 
kinases, it provides a possible target for manipulating cellular responses through ROS. 
Another example is NF-E2-related factor-2(Nrf2)-Keap1 complex, which functions as 
a ROS sensor and regulates the expression of antioxidant enzymes, such as catalase 
and glutathione peroxidase, through the binding of antioxidant response elements 
(AREs) in their 5’-flanking promoter regions (27, 28). Other factors, including NF- B, 
SP1, and YY1, are also involved in the regulation of redox-induced changes (29-31). 
Molecular oxygen could be considered as one substrate of energy production in 
mitochondria, but it is interesting to note that the derivative of oxygen, ROS, have 
been specifically linked to the regulation of the mitochondrial biogenesis. The 
peroxisome proliferator-activated receptor-gamma (PPARγ) coactivator‑1α (PGC1α) 
stimulates mitochondrial biogenesis in response to increased energy demand, while 
ROS promote its expression via Cre-binding protein (CREB); it also suggests that 
PGC1α regulates an antioxidant transcriptional program that includes SODs, catalase 
and GPX1 (192). PGC1α thus establishes an important link between ROS and 
mitochondrial respiration. Moreover, Forkhead box O (FOXO) transcription factors 
are key regulators in response to ROS, but also control the expression of critical 
enzymes which are involved in cellular energy homeostasis (240-242). Also, 
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mitochondrial ROS dictate the hypoxic activation of AMPK, which is a sensor of 
cellular energy status, found in metazoans and is known to be activated by the 
increased cellular AMP/ATP ratio (243, 244). It suggests that cells possess a delicate 
mechanism which controls ROS production and energy homeostasis as both are 
critical to maintain the normal metabolism. 
Cholesterol is an essential structural component of cells as well as a precursor of 
important hormones in animals. The biosynthesis of cholesterol is strictly under 
control to meet the cellular metabolic needs. As stated above, ROS widely influence 
cellular biological processes. It has been reported that 3-Hydroxy-3-methylglutaryl 
CoA (HMG CoA) reductase, the rate controlling enzyme of cholesterol biosynthesis, 
is activated by the cellular glutathione, an antioxidant peptide (107). ROS has been 
shown to activate the HMG CoA reductase by dephosphorylation mediated through 
activation of PP2A/p38/MAPK pathway, which is responsible for the age-related 
hypercholesterolemia as a result of increased ROS (245, 246). The suppression of 
ROS production by HMG CoA reductase inhibitors indicates the interesting link 
between ROS and the synthetic pathway (247, 248). Squalene epoxidase (SQLE), 
another rate limiting enzyme, catalyses the epoxidation of squalene to yield 
2,3-oxidosqualene in the process of cholesterol biosynthesis (249-251). Interestingly, 
the promoter region of SQLE gene contains the binding sites of SP1 and YY1, while 
the transcriptional activities of SP1 and YY1 are determined by the redox changes (30, 
31, 252). It may suggest the possible role of ROS in cholesterol biosynthesis.  
As ROS scavengers, antioxidant enzymes, including superoxide dismutase and 
glutathione peroxidase, significantly affect the levels of cellular ROS. The deficiencies 
or over expressions of these genes result in changes of ROS level with altered cellular 
signaling transductions as revealed by a variety of studies (4, 131, 253, 254). Our 
previous studies showed that the knockout of SOD1 caused hypercholesterolemia with 
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activated biosynthetic pathway in mice. Here, we hypothesized that ROS are primary 
factors responsible for the activation of cholesterol biosynthetic pathway, and may be 
a reason to cause hypercholesterolemia in mice. By using DQ as a superoxide 
generator, we found that DQ increased the gene expression of HMGCR and SQLE in 
the livers of mice as well as in HepG2 cells in in vitro studies.  
 
6.3 Experimental Design 
Treatment of animals and HepG2 cells.  WT mice, 8-10 weeks old, were injected 
intraperitoneally with phosphate-buffered saline (PBS) or DQ (10mg/kg and 30mg/kg 
BW) (n = 3-4 per treatment) and euthanized at 2h and 6h post-injection. HepG2 cells 
were cultured and maintained in DMEM medium as described previously. Cells were 
plated at a density of 1 x 106 cells per 100-mm-diameter culture dish. When the cells 
reached 60–70% confluence, the medium was replaced with experimental medium, 
containing 0, 0.25, 0.5 and 0.75 micromole DQ, respectively. After two hours’ 
incubation, cells were collected and RNA was extracted.  
Plasma cholesterol measurement.  Blood samples were collected from tails of live 
animals or from hearts after the mice were sacrificed. Plasma total cholesterol was 
measured as described previously.  
RNA extraction and RT-PCR.  Total RNA and cDNA were prepared by following 
the procedures stated in General Material and Methods section. PCR amplifications 
were carried out using a PTC-100TM Programmable Thermal Cycler with gene 
specific primers, as listed in Table 2.2. The total volume of reaction mixture was 25μl 
(2.5μl 10×buffer, 0.5μl each primer (10mM), 1μl 10mM dNTP and 1μl cDNA 
synthesis reaction product, 1.25U ExTaq polymerase and 19.25μl nuclease-free sterile 
water). PCR was performed at 95°C for 30 seconds, 60°C for 30 seconds, 72°C for 30 
seconds after initial incubations at 95°C for 5 minutes. The reactions were stopped in 
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the early linear phase which was previously evaluated. PCR products were analyzed 
on 2% agarose (Gibco BRL, Gaithersburg, MD, USA) gels with ethidium bromide 
staining at 1 mg/ml TAE buffer for 25 min followed by destaining for 5min with TAE 
buffer. The density of each band was measured and the values were normalized by 
18S of each sample.  
Nuclei isolation.  Nuclei were isolated from livers by Dounce homogenization and 
sucrose gradient centrifugation as described in the General Material and Methods 
section. 
Western blot.  Nuclei extract (10 μg of protein) was used for Western blot analysis 
as described in the General Material and Methods section. Antibodies used in these 
experiments were listed in Table 2.2.  
 
6.4 Results 
DQ treatment increased the plasma cholesterol in mice. Compared with PBS 
control, concentrations of plasma total cholesterol were increased (P < 0.05) by 23% 
and 29% in mice at two hours after treatments with 10mg/kg and 30mg/kg BW DQ, 
respectively (Figure 6.1). The average plasma total cholesterol was relatively higher in 
30mg/kg BW group than in 10mg/kg BW group. At 6 hours after treatment, mice 
injected with 10mg/kg BW DQ had 28% (P < 0.05) increase of plasma cholesterol, 
while mice injected with 30mg/kg BW DQ showed no increase, compared with the 
PBS control.  
Messenger RNA levels of HMGCR, SQLE and SREBP2 were increased in livers 
of mice treated with DQ as well as nuclear SREBP2 protein. As shown in Figure 
6.2, at 2 hours after treatment, mRNAs level of HMGCR, SQLE and SREBP2 were 
increased (P < 0.05) by 18, 13 and 22% in mice injected with 10mg/kg BW DQ, 
respectively. Of mice treated with 30mg/kg BW DQ, HMGCR, SQLE and SREBP2  
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Figure 6.1. Effect of DQ treatment on plasma cholesterol in mice. WT male mice were 
8~10 weeks old and injected intraperitoneally with PBS or DQ (10mg/kg BW and 
30mg/kg BW). Mice were sacrificed at 2 hours or 6 hours after injections and blood 
samples were collected from hearts with anti-coagulant EDTA, and plasma was 
immediately separated. Total cholesterol was measured by using a kit from Wako 
Chemicals USA Inc. Values are mean ± SE (n = 3). * P< 0.05 vs. PBS within the same 
time.  
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Figure 6.2. Effect of DQ on mRNA levels of hepatic HMGCR, SQLE and SREBP2 
after 2 hours of treatment. WT male mice were 8~10 weeks old and intraperitoneally 
injected with PBS or DQ (10mg/kg BW and 30mg/kg BW). Mice were sacrificed at 2 
hours after injections and livers were collected and stored at -80℃. Total RNA were 
extracted from the frozen livers as described previously. RT-PCR was conducted with 
gene specific primers as listed in Table 2.3. The amplicons were analyzed by agarose 
gel electrophoresis with EB staining. Density of each band was measured by using 
computerized software. Values of DQ treated samples (n = 3) were calculated as ratio 
to PBS control. * P< 0.05 vs. PBS; ** P < 0.01 vs. PBS within the same time.  
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were 42%, 23 and 19% higher (P < 0.05) than PBS control. As indicated by figure 6.3, 
at 6 hours after treatments, SQLE mRNA was consistently higher in the livers of mice 
treated with 10mg/kg BW or 30mg/kg BW DQ, compared with control; however, the 
mRNA levels of HMGCR and SREBP2 were decreased after the treatment, and were 
17% and 24% lower (P < 0.05) in the mice injected with 30mg/kg BW DQ as 
compared with PBS control. Figure 6.4 indicatesthat DQ treatment increased nuclear 
SREBP2, while decreased SREBP1 protein, in livers of mice after two hours of 
injection with 10mg/kg BW DQ.  
HepG2 responded to DQ treatment with increased mRNA of HMG CoA 
reductase. As indicated in Figure 6.5, there was a dose-dependent increase of HMG 
CoA reductase mRNA in HepG2 cells. The mRNA level of HMG CoA reductase was 
elevated by 17% (P < 0.05) when cells were subjected to 0.75 μM DQ for two hours 
and cell viability remained at 90% at the end of treatment as shown in Figure 6.5. 
 
6.5 Discussion 
The results indicate that superoxide-generator DQ elevated plasma total cholesterol 
and increased mRNA levels of cholesterol biosynthetic genes, HMG CoA reductase 
and squalene epoxidase, in the livers of mice at two hours after treatments with 
10mg/kg BW and 30mg/kg BW DQ. At the same time, DQ also increased the mRNA 
level of SREBP2 as well as level of nuclear SREBP2 protein. Similar responses were 
also observed in HepG2 cells where DQ treatment increased mRNA level of HMGCR. 
Consistent with our findings, xanthine/xanthine oxidase generated superoxide has 
been shown to activate the transcription of cholesterol biosynthesis pathway genes in 
human neuronal cells (255).  
To our surprise, DQ treatment was able to increase plasma total cholesterol within two 
hours, and the high dose treatment resulted in a stronger response. The increase of 
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Figure 6.3. Effect of DQ on mRNA levels of hepatic HMGCR, SQLE and SREBP2 
after 6 hours of treatment. WT male mice were 8~10 weeks old and intraperitoneally 
injected with PBS or DQ (10mg/kg BW and 30mg/kg BW). Mice were sacrificed at 6 
hours after injections and livers were collected and stored at -80℃. Total RNA was 
extracted from the frozen livers as described previously. RT-PCR was conducted with 
gene specific primers as listed in Table 2.3. The amplicons were analyzed by agarose 
gel electrophoresis with EB staining. Density of each band was measured. Values of 
DQ treated samples (n = 3) were calculated as ratio to that PBS control. * P< 0.05 vs. 
PBS within the same time.  
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Figure 6.4. Western blot analysis of SREBP1 and SREBP2 in the liver of WT mice 
treated with DQ. WT male mice were 8~10 weeks old and intraperitoneally injected 
with PBS or 10mg/kg BW DQ. Mice (n = 3) were sacrificed at 2 hours after injections 
and livers were collected for nuclei isolation as described previously. Western blot 
were conducted with 10 microgram nuclear proteins and membranes were probed with 
anti-SREBP1 and SREBP2 antibodies listed in Table 2.2.  
 
 
 
 
 
 
 
 
 
 
 99 
 
 
 
 
 
 
 
Figure 6.5. Expression of HMG CoA reductase gene in HepG2 cells treated with DQ. 
HepG2 cells were maintained in DMEM medium. When the cells reached 60–70% 
confluence, the medium was replaced with experimental medium, which containing 0, 
0.25, 0.5 and 0.75 micromole of DQ. After two hours’ incubation, cells were washed 
with warm PBS, and used for total RNA extraction or measuring cell viability. 
RT-PCR and agarose gel electrophoresis were performed as stated before. Values of 
DQ treated samples were calculated as ratio to that of non-treated. * P< 0.05 vs. 
non-treated. The figures represent one of three independent experiments with 
essentially the same results. 
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plasma total cholesterol in mice injected with low dose (10mg/kg BW) was observed 
at 6 hours after injection, while high dose (30mg/kg BW) did not produce similar 
effect. Similar responses were also observed at the level of mRNA. This intrigued us 
because the high dose DQ treatment showed stronger but shorter effect on plasma 
cholesterol than the low dose. It may indicate that cells have different mechanisms to 
cope with the different levels of DQ-induced stress, as observed by Haudek et al. 
(2008) (256). It is possible that week oxidative stress just tunes the metabolic 
pathways which are maximally changed under the extreme conditions. Another 
explanation for dose effect might be that plasma cholesterol is under the feedback 
control which promotes the clearance when the cholesterol concentration reaches a 
certain level. The feedback regulation of cholesterol biosynthesis has been well 
characterized in cells (257).  
Oxidative stress induced by DQ has been studied widely in animals (32, 258). DQ is a 
redox-cycling compound. It accepts an electron from NADPH-cytochrome P-450 
reductase in the ER of the hepatocytes and thereby becomes a free radical (259). The 
DQ radical recycles to the non-radical form by donating its unpaired electron to 
molecular oxygen (O2), producing superoxide (260). ROS generally account for the 
DQ induced metabolic changes. 
In the present study, ROS were found to affect the cholesterol biosynthesis at the 
transcriptional level as indicated by the increased mRNA levels of key cholesterol 
biosynthetic enzymes, including HMG CoA reductase and squalene epoxidase in 
mouse and HepG2 cells. In agreement with our results, Recuero et al., (2009) reported 
that ROS produced by xanthine/xanthine oxidase increased the mRNA levels of 
cholesterol biosynthetic genes in human neuronal cells (255). Moreover, ROS have 
been shown to regulate the enzymatic activity of HMG CoA reductase by certain 
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modifications (245, 246). Therefore, ROS might be involved in the regulation of the 
cholesterol biosynthesis on transcriptional and post-translational levels. 
Further, at the first time, we report that ROS increased SREBP2 mRNA and nuclear 
protein levels in the livers of mice. There are three different SREBPs: SREBP-1a, -1c 
and -2. SREBP-1a and -1c are isoforms produced from a single gene by alternate 
splicing (69). SREBP
 
2 isoform preferentially regulates genes involved in cholesterol
 
homeostasis including all the cholesterol biosynthetic enzymes while SREBP1c 
mainly controls the fatty acid synthesis (127). Under normal conditions, SREBPs are 
activated and translocated into nuclei after the processes of translocation and protease 
cleavage when cellular cholesterol is depleted, and suppressed by the replete 
cholesterol (77, 78). This is considered as a major regulatory mechanism of SREBPs 
while other regulations are also suggested, including phosphorylation and sumylation, 
which affected its activity and stability in nuclei (129, 228). In addition, the 
transcription of SREBP2 is under its own control. Therefore, the increased nuclear 
SREBP2 accounted for, at least partially, the increased mRNA of HMGCR and SQLE 
in the liver of mice treated with DQ. 
Interestingly, DQ treatment increased SREBP2 but reduced SREBP1 in hepatic nuclei 
of mice. The balance between SREBP1 and SREBP2 are important in maintaining the 
normal lipids biosynthesis, as demonstrated by Shimano et al., (1997) (159, 226). The 
changes induced by DQ might represent the cellular priorities of metabolic needs in 
order to survive the unfavorable condition, and SREBP 1 and 2 serve as the switch to 
direct energy to the critical reactions. It also is proposed as a survival strategy for 
yeast that the activation of SREBP homologue in yeast, which induces the synthesis of 
sterol, under hypoxia is a necessary process for cells to survive through the adverse 
condition (75, 158). 
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In summary, our results demonstrated that DQ induced oxidative stress increased 
plasma cholesterol, and elevated HMG CoA and squalene epoxidase transcription in 
the liver of mice as well in HepG2 cells, which may be mediated, at least partially, by 
increasing nuclear SREBP2. These findings suggest that ROS play an importance role 
in regulation of cholesterol biosynthesis, and SREBP2 may mediate this response. 
This study makes ROS generators or scavengers potentially useful for clinical usage in 
order to interfere with problems related to cholesterol biosynthesis. 
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CHAPTER SEVEN 
SUMMARY AND GENERAL DISCUSSION 
Antioxidant enzymes play important roles in maintaining the cellular redox 
homeostasis and protecting cells from the damage caused by ROS. The deficiencies of 
antioxidant enzymes cause various health problems in animals due to the 
consequences of disrupted redox balance. ROS, which could be toxic or function as 
cellular signaling molecules, carry the primary interest in the exploration of 
antioxidant deficiency induced biological alterations. Several transcriptional factors, 
enzymes and small antioxidant molecules have been identified as ROS responsive 
agents that mediate the signal transduction of ROS although the exact regulatory 
mechanism remains largely unknown. 
SOD1, mainly located in cytosol, has been appreciated for decades as an important 
antioxidant enzyme in the clearance of superoxide. Generally, superoxide is converted 
into hydrogen peroxide by superoxide dismutase and the latter is further converted to 
water by glutathione peroxide or catalase. Apparently SOD1 regulates the cellular 
level of superoxide and could influence the cellular redox balance. Numbers of studies 
show that the deficiency of SOD1 leads to abnormities of different tissues and organs 
in the genetic knockout models (2-9). The abnormal lipid deposition in liver and heart 
discovered in many studies indicates the potential role of SOD1 in lipid metabolism (9, 
121). The association or indirect link between ROS and energy or lipid metabolism 
also suggested the possible regulatory role of SOD1 (192, 240-244). Obesity model 
caused by over expression of glutathione peroxidase 1, discovered in our lab, strongly 
supports the importance of redox balance in the regulation of energy and lipid 
homeostasis (131). The accidental observation of severe dyslipidemia in SOD1 mice 
further intrigued us to investigate the metabolic change, specifically lipid metabolism, 
caused by the knockout of SOD1 and the molecular mechanism behind this interesting 
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phenotype. This dissertation was aimed to demonstrate the indispensible role of SOD1 
in maintaining the normal lipid metabolism. 
To address the question of the regulatory role of SOD1 in lipid metabolism and 
explore possible strategies to counteract the abnormal changes induced by the 
knockout of SOD1, several hypotheses have been developed and examined by 
separate studies with different approaches. The activation of cholesterol biosynthetic 
pathway significantly attracted our attention because of the biological significance of 
cholesterol. It is known that both fatty acids and cholesterol are synthesized with 
difference pathways. However, both pathways begin with the same substrate, cellular 
acetyl CoA, which is the small unit of energy in cells. While cholesterol is well known 
as an essential structural component of cells and a precursor of important hormones, it 
is possible that it is also used as an energy carrier for storage or excretion, where 
cholesterol synthesis is activated under the positive energy balance as an alternative 
way to store or eliminate the excessive energy. It seemed to really happen in SOD-/- 
mice as stated in Chapter Three, which drove us to exam the cholesterol biosynthetic 
pathway closely in the following studies, where triglyceride was also included. 
In Chapter Three, the lipid disorder was first characterized in both young and adult 
SOD1-/- mice followed by molecular measurements of related pathways. The 
knockout of SOD1 causes hypercholesterolemia and hypotriglyceridemia with 
irregular lipid accumulation in liver, heart, kidney, muscle and testis. In contrast to the 
suppressed accumulation of fatty acids/triglyceride, the cholesterol synthetic pathway 
was consistently activated in SOD1-/- mice as indicated by increased mRNA and 
protein levels of related genes at 3 wk and 9 wk of age. The significant increase of 
SREBP2 and decrease of SREBP1 in SOD1-/- mice suggested the switch-like function 
of these two proteins under unfavorable conditions. It was obvious that the knockout 
of SOD1 shifted the energy from fatty acid/triglyceride into cholesterol synthesis by 
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activation the classical biosynthetic pathway. 
In Chapter Four, experiments were designed to test the hypothesis that the metabolic 
changes induced by the knockout of SOD1 depended on dietary energy, which could 
be reversed by high fat diet. However, high fat diet reduced body weight of SOD1-/- 
mice by 17% and (V)LDL triglyceride by 15%, although the plasma total cholesterol, 
total triglyceride and fecal cholesterol in SOD1-/- mice were not significantly affected. 
High fat diet significantly increased levels of nuclear SREBP1 and SREBP2 proteins 
in both genotypes while did not reverse the trend induced by SOD1-/- under normal 
feeding. These results indicate that the increased dietary energy did not reverse the 
metabolic changes and the activation of cholesterol biosynthesis might not be affected 
by high fat diet in SOD1-/- mice. 
In Chapter Five, experiments were conducted to test the hypothesis that dietary Cu 
may counteract the metabolic changes induced by the knockout of SOD1 as SOD1 is 
the major Cu-containing protein. Interestingly, Cu deficiency did not affect the 
concentrations of blood lipids in SOD1-/- mice while high Cu was only found to 
reduce hepatic triglyceride with no effect on plasma cholesterol and triglyceride and 
hepatic cholesterol. An additional finding was that the expression of SOD1 protein 
was negatively related to dietary Cu level in WT mice, which was opposite to the 
changes of total enzyme activity. SREBPs proteins showed remarkable changes but 
only partially matched the predictions of the phenotype. Therefore, dietary 
supplementation of excess Cu was unable to reverse the consequence of SOD1 
deficiency in mice. 
In Chapter Six, experiments were conducted to test the hypothesis that ROS were the 
primary factors in regulation of cholesterol biosynthesis as observed in the SOD1-/- 
mice. Surprisingly, significant increases, of 23% and 29%, total plasma cholesterol 
were observed within two hours in mice injected with DQ at 10mg/kg BW and 
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30mg/kg BW, respectively; we also found that mRNA of HMG CoA reductase and 
squalene epoxidase were elevated by 18% and 13%, respectively, compared with 
control. HepG2 cells also showed a similar response to DQ treatment with increased 
HMGCR mRNA levels. These results suggest that ROS may play an important role in 
regulation of cholesterol biosynthesis which is possibly mediated by SREBP2.  
The lipid disorder in SOD1-/- mice did not depend on age and diets. Oxidative stress 
induced by DQ showed positive effects on the transcription of cholesterol biosynthetic 
genes in mice and cells model as well as on the concentrations of plasma cholesterol in 
mice. Oxidative stress have been shown to increase with impaired SOD1 activity in 
animals on the Cu deficient diet, which also increased plasma cholesterol as a result of 
elevated biosynthesis. This may suggest that the loss of SOD1 activity is the primary 
factor of Cu deficiency-induced lipid disorder.   
High fat diet has also been reported to increase oxidative stress in animals, while 
similar increase is observed in obese patients (164, 181-183, 213, 261-263). High fat 
diet may aggravate oxidative stress in SOD1-/- mice, which could explain the further 
loss of body weight and reduced plasma triglyceride. Therefore, extra caution should 
be taken in using high fat diet to improve body weight of patients whose antioxidant 
system is impaired. 
This dissertation indicates a possible way to interfere with lipid metabolism by SOD1 
or ROS generators, which could switch fatty acid synthesis to cholesterol synthesis 
and the latter could be degraded or excreted from bodies. This work provides 
promising tools for treating obesity. However, the detrimental effect of oxidative stress 
should also be considered. 
In summary, the major findings of this dissertation include: 1) knockout of SOD1 
caused dyslipidemia as well as abnormal cholesterol and triglyceride deposition 
among tissues and organs; 2) SOD1 deficiency activated cholesterol biosynthetic 
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pathway and was transcriptionally associated with increased SREBP2 protein; 3) 
knockout of SOD1 altered the ratio of SREBP1 and SREBP2 proteins as well as their 
target genes and plasma cholesterol and triglyceride; 4) high fat diet exacerbated the 
loss of body weight in SOD1-/- mice without benefits on the lipid disorder; 5) dietary 
excess Cu did not rescue the lipid disorder in SOD1-/- mice while the similarities of 
hypercholesterolemia caused by dietary Cu deficiency and by knockout of SOD1were 
observed; 6) the DQ-induced oxidative stress elevated the plasma cholesterol along 
with increased transcription of cholesterol synthetic genes in vivo and in vitro. It could 
be concluded that the impaired lipid metabolism in the SOD1-/- mice resulted from the 
loss of SOD1 function in scavenging superoxide anion.. However, further studies are 
needed to dissect the exact molecular mechanism of the regulatory role of SOD1 and 
its interaction with ROS in lipid metabolism. 
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